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ABSTRACT 
PROJECT I: Role of lncRNAs in the regulation of DNA repair. 
DNA damage is a lethal and common event during the lifetime of a cell, and in 
view of its repair, some specific pathways have evolved, integrating the general DNA 
damage response (DDR). As expected, DNA repair alterations have been extensively 
correlated with cancer; and in particular colorectal cancer (CRC), which often presents 
genome instability due to DNA mismatch repair (MMR) deficiency. In contrast with MMR, 
the role played by other DNA repair pathways in CRC are not so well reviewed. In a 
comprehensive study by Slyskova et al (2012)1, base and nucleotide excision repair 
pathways (BER and NER, respectively) were found not to be considerably altered in 
CRC. However, to further investigate the possible involvement of excision repair in CRC, 
an epigenetic analysis considering the biggest and less studied class of transcripts was 
proposed. Long non-coding RNAs (lncRNAs) are a miscellaneous class of multi-
functional RNA molecules that has been recently correlated with CRC and also with 
DDR. Therefore, the purpose of this project was the discovery of BER-related lncRNAs, 
which could represent new biomarkers or treatment-targets in CRC. 
The same CRC tissue samples from Slyskova et al (2012) were used along with 
the obtained data to generate four distinct groups with five elements each, divided 
according to lower and higher DNA repair capacity (DRC) measurements in both cancer 
and adjacent healthy tissues. Using a LncProfiler qPCR Array®, the levels of ninety 
lncRNAs were measured for each of the twenty selected samples, and next analysed for 
statistically significant expression differences. 
This analysis revealed the inexistence of significant differences: neither between 
each pair of groups compared, nor between all tumour versus normal mucosa samples 
or lower DRC versus higher DRC; due to the small size of the series and high inter-
variability. Hence, although these results indicate that no possible role exists for the 
tested lncRNAs in CRC tumourigenesis in association with BER functionality, no solid 
conclusions can be stated. 
 
PROJECT II: Evaluation of CIMP status in colorectal cancer and 
correlation with prognosis. 
Colorectal cancer (CRC) is one of the major causes of cancer-related morbidity 
and mortality worldwide. Despite of recent advances in treatment approaches, cancer 
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progression and metastization still remains a major concern. This heterogeneous 
disease is currently classified according to global genomic or epigenomic status, which 
have been linked to different clinicopathologic characteristics, prognosis and treatment 
response. Therefore, segregation of CRC patients by their molecular phenotype is 
essential to predict those who will benefit from a specific therapy. A subset of CRC 
patients has been shown to exhibit widespread promoter CpG island methylation, termed 
CpG Island Methylator Phenotype (CIMP). For instance, CIMP has been increasingly 
referred as a promising prognostic factor. However, it is the less understood molecular 
subtype in CRC and various methods and definitions have been used to categorize CIMP 
status, leading to discrepancies. To further assess this issue, new integrative studies are 
required. Thus, the main goal of this project was CIMP profiling and the analysis of a 
series of 211 patients diagnosed with sporadic CRC. 
DNA extracted from 211 CRC and 43 healthy mucosa samples, formalin fixed 
paraffin embedded, was bisulfite converted, and promoter methylation of five genes/loci 
was then assessed by real-time qMSP (SYBR® Green-based), for CIMP frequency. 
Further statistical analysis to disclose associations with clinicopathological parameters, 
and survival analyses to evaluate CIMP prognostic value were conducted. 
CIMP was found in 8.5% of all CRC cases and did not associate with any of the 
studied clinicopathological and molecular variables. Furthermore, CIMP did not 
associate with patients’ prognosis, both for disease-specific survival (DSS) (HR 1.192 
95% CI 0.732-1.941, P=0.481) or disease-free-survival (DFS) (HR 0.554 95% CI 0.241-
1.275, P=0.161). However, aberrant methylation of one of the five markers constituting 
the selected panel, CDKN2A(p16), associated with shorter DSS, but only in univariable 
analysis (HR 1.578 95% CI 1.016-2.450, P=0.042). 
CIMP status did not associate with patients’ survival, which is in accordance with 
previous studies by others. However, the laboratory technique or its application with the 
specific panel selected may not be adequate to evaluate CIMP status, yielding lower 
CIMP frequencies and further lack of significant associations between CIMP and any of 
the recorded variables. Additional studies are needed to further confirm these preliminary 
results. 
 
Keywords: Epigenetics, colorectal cancer, lncRNAs, base-excision repair, methylation, 
CIMP, prognosis. 
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RESUMO 
PROJETO I: Papel dos lncRNAs na regulação da reparação do 
ADN. 
Os danos no ADN são um evento letal e comum durante o tempo de vida de uma 
célula, e tendo em vista a sua reparação, algumas vias específicas evoluíram, 
integrando no geral a resposta a danos no ADN (DNA damage response – DDR). Como 
esperado, alterações na reparação do ADN têm sido extensivamente correlacionadas 
com o cancro; e, em particular o cancro colorectal (CCR), que muitas vezes apresenta 
instabilidade genómica devido a defeitos na via de reparação de desemparelhamentos 
(mismatch repair – MMR). Em contraste com a via MMR, o papel desempenhado por 
outros mecanismos de reparação do DNA no CCR não está tão bem revisto. Num 
estudo abrangente por Slyskova et al (2012)1, as vias de reparação por excisão de bases 
ou nucleótidos (base-excision repair – BER e nucleotide-excision repair – NER, 
respetivamente) não foram consideradas notavelmente alteradas no CCR. No entanto, 
para investigar o possível envolvimento da reparação por excisão no CCR, foi proposta 
uma análise epigenética tendo em conta a maior e menos estudada classe de 
transcritos. ARNs não-codificantes longos (long non-coding RNAs – lncRNAs) são uma 
classe variada de moléculas de ARN multifuncionais que foi recentemente 
correlacionada com o CCR e também com DDR. Portanto, o objetivo deste projeto foi a 
descoberta de lncRNAs relacionadas com a via BER, que poderão representar novos 
biomarcadores ou alvos de tratamento para o CCR. 
As mesmas amostras de tecido de CCR estudadas em Slyskova et al (2012), 
juntamente com a respetiva informação obtida, foram utilizadas para criar quatro grupos 
distintos, com cinco elementos cada, divididos de acordo com uma menor ou maior 
capacidade de reparação do ADN (DNA repair capacity – DRC) – determinada tanto no 
tecido tumoral como da mucosa normal adjacente. Usando LncProfiler qPCR Array®, 
os níveis de noventa lncRNAs foram medidos para cada uma das vinte amostras 
selecionadas, e em seguida analisados relativamente à existência de diferenças 
estatisticamente significativas na expressão. 
Esta análise revelou a inexistência de diferenças significativas: nem entre cada 
par de grupos comparados, nem entre todas as amostras tumorais versus amostras de 
mucosa normal, ou menor DRC versus maior DRC, devido ao reduzido tamanho 
amostral e à elevada inter-variabilidade. Assim, embora estes resultados indiquem que 
não existe qualquer papel para os lncRNAs testados na tumorigénese do CCR em 
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associação com a funcionalidade da via BER, não podem ser apontadas conclusões 
sólidas. 
 
PROJECT II: Avaliação do perfil CIMP no cancro colorectal e 
correlação com prognóstico. 
O cancro colorectal (CCR) é uma das principais causas de morbidade e 
mortalidade relativas a cancro no mundo. Apesar dos recentes avanços de abordagens 
terapêuticas, progressão do cancro e metastização ainda persistem como a principal 
preocupação. Esta doença heterogênea é atualmente classificada em função do estado 
genético e epigenético global, o que tem sido associado com diferentes características 
clinicopatológicas, prognóstico e tratamento. Assim, a segregação de pacientes com 
CCR pelo seu fenótipo molecular é essencial para prever aqueles que irão beneficiar de 
uma terapia específica. Um subconjunto de pacientes com CCR demonstrou exibir 
metilação generalizada em ilhas CpG de promotores, o que foi denominado Fenótipo 
Metilador de Ilhas CpG (CpG Island Methylator Phenotype – CIMP). Efetivamente, CIMP 
tem sido, cada vez mais, referido como um promissor fator de prognóstico. No entanto, 
é o subtipo molecular menos compreendido no CCR, e várias definições e métodos têm 
sido utilizados para categorizar o perfil CIMP, conduzindo a discrepâncias. Para avaliar 
mais profundadamente esta questão, novos estudos integrativos são necessários. 
Assim, o objetivo principal deste projeto foi o profiling de CIMP numa série de 211 
pacientes diagnosticados com CCR esporádico. 
ADN extraído a partir de 211 CCRs e 43 amostras de mucosa saudável, fixados 
em formol e embebidos em parafina, foi convertido pela técnica de bissulfito, e a 
metilação dos promotores de cinco genes/loci foi então determinada por qMSP em 
tempo real (baseada em SYBR® Green), para avaliar a frequência de CIMP. Foram 
então realizadas análises estatísticas para revelar associações com parâmetros clínico-
patológicos, e análises de sobrevivência para avaliar o valor prognóstico de CIMP. 
CIMP foi encontrado em 8,5% de todos os casos de CCR e não foi associado 
com qualquer dos parâmetros clinicopatológicos e moleculares analisados. Além disso, 
CIMP não foi também associado com o prognóstico dos pacientes, tanto no caso da 
sobrevivência específica de doença (HR 1,192; CI 95% 0,732-1,941; P = 0,481), como 
da sobrevivência livre de doença (HR 0,554; CI 95% 0.241-1,275; P=0,161). No entanto, 
metilação aberrante de um dos cinco marcadores que constituem o painel selecionado, 
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CDKN2A(p16), foi associada com menor sobrevivência específica de doença, mas 
apenas em análise univariável (HR 1,578; CI 95% 1,016-2,450; P=0,042). 
O fenótipo CIMP não foi associado com a sobrevivência dos pacientes, o que 
está de acordo com outros estudos anteriores. Contudo, a técnica de laboratório ou a 
sua aplicação com o painel específico selecionado podem não ser adequadas para 
avaliar o perfil CIMP, levando a frequências de CIMP mais baixas e à ausência de 
associação entre CIMP e qualquer um dos parâmetros testados. Estudos adicionais são 
precisos para confirmar estes resultados preliminares. 
 
Palavras-chave: Epigenética, cancro colorectal, lncRNAs, reparação por excisão de 
bases, metilação, CIMP, prognóstico. 
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IGFBP3 – Insulin-Like Growth Factor-Binding Protein 3 
IGFR – Insulin-Like Growth Factor 1 Receptor  
IHC – Immunohistochemistry 
INK4 –  Family of Inhibitors of Cyclin-Dependent Kinase 4 
Jpx – JPX Transcript, XIST Activator (Non-Protein Coding) 
KRAS – Gtpase KRAS (V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog) 
LET – Low Expression in Tumour 
LIG3 – DNA Ligase 3 
LincRNA – Long Intergenic Non-coding RNA 
LINE-1 – Long Interspersed Element-1 
LncRNA-DDSR1 – Long non-coding RNA-DNA Damage-Sensitive RNA1 
LncRNA-JADE – Long non-coding RNA- Jade Family PHD Finger 1 
LncRNAs – Long non-coding RNAs 
LOH – Loss of Heterozygosity 
LOI – Loss of Imprinting 
LSD1 – Lysine-Specific Demethylase 1 
LUST – LUCA-15-Specific Transcript 
M – Methylated 
MALAT1 – Metastasis-Associated Lung Adenocarcinoma Transcript 1 
MAP – MUTYH-Associated Polyposis 
MAPK – Mitogen-Activated Protein Kinase 
mascRNA – MALAT1-Associated Small Cytoplasmic RNA 
MBD4 – Methyl-CpG-binding domain protein 4 
MDM2 – Mouse Double Minute 2 
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MEG3 – Maternally-Expressed Gene 3 
MEG9 – Maternally Expressed 9 
MEK – Map Kinase Kinase 
MGMT – O6-Methylguanine DNA Methyltransferase 
MINT– Methylated-in-Tumor  
miRNA – MicroRNAs 
MLH1 – MutL Homolog 1 
MMR – Mismatch Repair 
MRC – Magnetic Resonance Colonography 
mRNA – Messenger RNA 
MSH2/6 – MutS Protein Homolog 2/6 
MSI – Microsatellite Instability 
MSI-H – Microsatellite Instability-High 
MSI-L – Microsatellite Instability-Low 
MSP – Methylation-Specific Polymerase Chain reaction 
MSS – Microsatellite Stable 
MTOR – Mechanistic Target of Rapamycin 
MUTYH – MutY DNA Glycosylase 
MYLKP1 – Myosin Light Chain Kinase Pseudogene 1 
MYOD1 – Myogenic Differentiation 1 
NcRNAs – Non-coding RNAs 
NDRG4 – N-Myc Downstream-Regulated Gene 4 Protein 
NEIL1 – Nei Endonuclease VIII-Like 1 
NER – Nucleotide Excision Repair 
NEUROG1 – Neurogenin 1 
NF-KB – Nuclear Factor Kappa B) 
NGFR – Nerve Growth Factor Receptor 
NHEJ – Non-Homologous End-joining 
NRAS – Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog 
NSAIDS – Nonsteroidal Anti-Inflammatory Drugs 
NuRD – Nucleosome Remodelling and Histone Deacetylase 
ORFs – Open-reading Frames 
OS – Overall Survival 
P400 – EP400 E1A Binding Protein P400 
PALB2 – Partner and Localizer of BRCA2 
PARP – Poly (ADP-ribose) Polymerase 
PBMCs – Peripheral Blood Mononuclear Cells 
PCAT-1 – Prostate Cancer-Associated Transcript 1 
PI3K – Phosphoinositide 3-kinase 
PIK3CA – Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Alpha 
PMS2 – PMS1 Homolog 2, Mismatch Repair System Component 
PRCs – Polycomb Repressive Complexes 
PTBP2 – Polypyrimidine Tract Binding Protein 2 
PTEN – Phosphatase and Tensin Homolog 
PTENP1 – Phosphatase and Tensin Homolog Pseudogene 1 
PTGS2 – Prostaglandin-Endoperoxide Synthase 2 
PVT1 – Plasmacytoma Variant Translocation 1 
qMSP –  Quantitative Methylation-Specific Polymerase Chain reaction 
qPCR –  Quantitative Polymerase Chain Reaction 
RAD51 – RAD51 Recombinase 
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RAP80 – Receptor-Associated Protein 80 
RASSF1A – Ras Association Domain-Containing Protein 1Isoform A/B 
RET – Ret Proto-Oncogene 
RFS – Recurrence-free Survival 
RISC – RNA-Induced Silencing Complex 
RNA – Ribonucleic Acid 
RNCR3 – Retinal Noncoding RNA 3 
RT – Radiotherapy 
RTK – Receptor Tyrosine Kinase 
RUNX3 – Runt Related Transcription Factor 3 
SAF – LncRNA Fas-Antisense 1 (Fas-AS1) 
SEPT9 – Septin 9  
SETD2 – SET Domain Containing 2 
SFPQ – Splicing Factor Proline/Glutamine-Rich 
SFRP1 – Secreted Frizzled-Related Protein 1/2 
SIRT1 – Sirtuin 1 
SLIT2 – Slit Guidance Ligand 2 
Smad – Mothers Against Decapentaplegic 
SMARCC2 – SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin 
Subfamily C Member 2 
SNHG4 – Small Nucleolar RNA Host Gene 4 
snoRNAs – Small Nucleolar RNAs 
SNPs – Single-Nucleotide Polymorfisms 
SOCS1 – Suppressor of Cytokine Signaling 1 
SOX9 – SRY-Box 9 Transcription Factor 
ssDNA –Single Strand DNA 
STAT – Signal Transducer and Activator of Transcription 
SV2C – Synaptic Vesicle Glycoprotein 2C 
SWI/SNF – SWItch/Sucrose Non-Fermentable 
T – Thymine 
TCF7L2 – Transcription Factor 7-Like 2 
TFPI2 – Tissue Factor Pathway Inhibitor 2 
TGF-β – Transforming Growth Factor-Beta 
TGFBR – Transforming Growth Factor-Beta Receptor  
TH – Tumour with Higher Levels of BER Repair Capacity 
TL – Tumour with Lower Levels of BER Repair Capacity 
TMEFF2 – Transmembrane Protein with EGF Like and Two Follistatin Like Domains 2 
TODRA – Transcribed in the Opposite Direction of RAD51 
TP53 – Tumour Protein P53 
TUSC7 – Tumour Suppressor Candidate 7 
U – Uracil 
UM – Unmethylated 
VEGF – Vascular Endothelial Growth Factor 
VIM – Vimentin 
WHO – World Health Organization 
WIF – WNT Inhibitory Factor 
WNT – Wingless/Integrated 
WT – Wild-Type 
XRCC1 – X-Ray Repair Cross-Complementing Protein 1 
Zfas1 – Zinc Finger Antisense 1 
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INTRODUCTION 
COLORECTAL CANCER: GENERAL ASPECTS 
Epidemiology and risk factors 
Cancer was responsible for 8.2 million deaths in 2012, being the second leading 
cause of mortality worldwide, and 14 million new cases diagnosed in 2012. Malignant 
neoplasms originating in both rectum and colon are typically joint under the same general 
designation, representing the third most frequently diagnosed type of cancer in both 
sexes (9.7%) or in men (10.0%), and the second among women (9.2%). After lung, liver 
and stomach, it is the major cause of cancer-related deaths (8.5%). Regardless of earlier 
detection following improved and wider screening over the past two decades in Europe, 
as well as effective treatment options, almost half of all individuals diagnosed with CRC 
die as a result of the disease.2–4 Analysing specifically the Portuguese population, CRC 
represents the most frequent and the major cause of death by cancer (14.5% and 15.7%, 
respectively) (online analysis at globocan.iarc.fr). 
Generally, males are slightly more affected than females (incidence and 
mortality), and present an average age of earlier onset, which could be attributed to 
differences at the hormonal level and environmental risk factors predisposition.5–7 
However, contrarily to age, gender is not a relevant clinical feature in the assessment of 
CRC predisposition. Indeed, according to the American Cancer Society the likelihood for 
individuals under 40 years old to develop CRC is 1:1.212, as opposed to 1:24 for 
individuals over 70. Moreover, 90% of all cases diagnosed and 93% of deaths were 50 
and older.6,8 Therefore, current recommendations for CRC screening are set to start at 
50 years for both women and men. However, contrarily to older individuals, incidence 
rates in adults younger than 50 years has been increasing, likely related to modern 
acquired unhealthy habits and dietary, such as sedentary life, overload of calories and 
animal fat consumption. Perhaps unsurprisingly, Europe and Americas account for more 
than half of all CRC cases.2,6,9 Indeed, CRC is considered primarily as a “lifestyle” 
disease. Behavioural factors associated with increased risk include mainly a diet high in 
red or processed meat, but also obesity (measured by waist size), physical inactivity, 
heavy alcohol consumption, long-term smoking, and very low intake of fruits and 
vegetables. In its turn, higher blood levels of vitamin D, physical activity, higher intake of 
dietary fibber, cereal fibber and whole grains, fruit and vegetables, dairy products, milk, 
garlic and calcium, and dietary folate have been proposed to be protective. Although not 
recommended for CRC prevention, regular use of nonsteroidal anti-inflammatory drugs 
(NSAIDS), postmenopausal hormones, oral contraceptives and oral bisphosphonates 
have also been associated with a decreased risk. However, for most of these, 
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contradictory results published or lack of strong evidence and molecular explanation 
limits their applicability.2,6,10 For example, folate deficiency was shown to result in 
aberrant DNA methylation, mutations and chromosomal aberrations, but some studies 
failed to prove a positive correlation, while some others attributed a negative effect to 
folic acid fortification/supplementation.10,11 
 
Methods of diagnosis 
An early detection of the lesion is fundamental. A significant proportion of CRC 
patients are diagnosed with a regional or metastatic stage of the disease.6 Screening 
programmes are increasing and include both invasive and non-invasive tests. guaiac 
Faecal Occult Blood Test (gFOBT) and Faecal Immunochemical Test for haemoglobin 
(FIT) are based on stool analysis and therefore usually more tolerable, with 
demonstrated mortality reduction.3 However, their sensitivity for advanced adenomas 
and cancer is low to moderate (worse in the case of gFOBT), and their effectiveness is 
highly dependent on positivity cut-off level.3,12 Both techniques have been used as initial 
screening followed by colonoscopy to confirm positive cases. Such approach appears to 
be more costly-effective than colonoscopy only. Although highly invasive and costly, 
colonoscopy is still the preferable option due to a high sensitivity coupled with immediate 
polyp resection, ampler test time intervals and better outcomes.6 Other less extensively 
explored procedures such as Flexible Sigmoidoscopy (FS), Colon Capsule Endoscopy 
(CCE), Computed Tomographic Colonography (CTC) and Magnetic Resonance 
Colonography (MRC) are predicted to be important alternatives to colonoscopy 
screening. Future research will focus on DNA, RNA and protein biomarkers in blood and 
stool based tests with higher sensitivity.3,6 
 
Histology and molecular etiology 
Before focusing on CRC prognosis and treatment, it is important to pathologically 
characterize CRC and describe its classification and diverse etiology. In fact, CRC is a 
heterogeneous disease in terms of clinical behaviour and response to therapy, which 
correlates with distinct underlying molecular mechanisms and origin.13 The colon (large 
intestine) measures almost 150 cm and consists of 4 segments: cecum and vermiform 
appendix, colon (ascending, transverse, and descending portions), rectum, and anus. It 
is commonly divided in proximal or right-sided colon (cecum, ascending colon, hepatic 
flexure, transverse colon, splenic flexure), distal or left-sided colon (descending colon 
and sigmoid colon), and rectum (rectosigmoid junction and rectum) [Fig.1].14 
Increasingly, it is being recognized that CRC risk factors, tumour characteristics, and 
response to treatment may vary across anatomic subsites, mainly between rectum and 
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the rest of the colon.15 Of mention, proximal colon cancers are most common in females, 
older patients with mucinous histology, while distal cancers occur more often among 
males and younger individuals presenting predominantly absorptive histology.5,16,17 
Histologically, the intestine wall comprises the sequence: mucosa, submucosa, 
muscularis (or muscularis propria), subserosa and serosa [Fig.1].14 The great majority 
(circa 96%) of CRC are adenocarcinomas. Each one of these tumours may take a period 
of 30 to 60 years to initiate, plus 1-5 years to 2 decades to progress from previous benign 
lesions, known as polyps (most of which are adenomas). The fastest step is 
metastization, which may occur a few years after or almost simultaneously with 
completion of malignant transformation of the primary CRC.18,19 Although common, less 
than 10% of adenomas transform into adenocarcinomas. These adenomatous structures 
arise from glandular cells on the epithelium and can grow through the inner layers of the 
intestinal wall eventually invading other regional structures as lymph nodes, blood or 
lymph vessels, and ultimately metastasize. Liver is the primary metastatic site, followed 
by lung. The extent to which cancer has spread at the time of diagnosis is essential to 
define its stage and further select treatment and assess prognosis [see Fig.1, Table 
1].6,20,21	
	
Fig.1 - Distribution of CRC by anatomical site; illustrative CRC staging, and large intestine wall histological layers. 
Approximate frequencies (%) of CRC along colon, rectum and anus.22 First onset picture depicts the five AJCC stages, 
with red spheres representing regional lymph nodes invasion and metastasis. (Adapted from National Cancer Institute). 
The second onset represents the histological division of the large intestine wall, from the lumen to the peritoneum: mucosa 
(including surface epithelium, lamina propria and muscularis mucosae), submucosa, muscularis (propria) (with two 
differently directed muscle layers), subserosa and serosa. (Adapted from AJCC – 7th Edition Staging Posters). 
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About 75% of all CRC cases have no apparent predisposing etiology, whereas 
the remaining cases are related to familial/hereditary syndromes and Inflammatory 
Bowel Disease (IBD). Familial CRC includes known hereditary forms, such as Familial 
Adenomatous Polyposis (FAP), Hereditary Nonpolyposis Colorectal Cancer (HNPCC – 
also known as Lynch syndrome), MUTYH-Associated Polyposis (MAP), and the 
hamartomatous polyposis syndromes. The majority of familial cases have no clearly 
identifiable genetic etiology, but it likely comprises less penetrant variations or Single-
Nucleotide Polymorfisms (SNPs).23,24The approximate percentage of distribution for 
each condition is as follows: sporadic, ~75%; familial (not known), ~15%; HNPCC, <5%; 
FAP, ~1%; IBD, ~1%; MAP, ~1%; hamartomas, <1%.24 Focusing on sporadic CRC, it 
can be divided in hypermutated (16%) and non-hypermutated (84%). Particularly, 
tumours from the right/ascending colon are more prone to be hypermethylated and to 
display elevated mutation rates.25  
Almost 30 years ago, Fearon and Vogelstein described a simplified multistep 
model for the formation of adenocarcinomas from normal mucosa. The model was based 
on the total accumulation of multiple genetic mutations leading to a selective growth 
advantage of those cells, with a minimum number of different mutations required – 
affecting mostly cell proliferation or DNA damage response (DDR).26 Adenomatous 
polyposis coli (APC) inactivation,	which is responsible for FAP and approximately 85% 
of sporadic CRC mutations, represents the initiating event in adenoma formation, which 
is followed by accumulation of multiple mutations inactivating other tumour suppressors 
and activating particular oncogenes. Loss of APC or, rarely, mutational activation of β-
catenin (CTNNB1), leads to an aberrant activation of the Wnt pathway. After this 
dysplastic phase, adenoma evolution depends on sequential mutations of KRAS (35-
45%) or BRAF (V600E mostly, 8-12%), causing EGFR signalling activation; SMAD2/4 
(10-35%) or TGFBR2, which inactivates TGF-β response; and TP53 (35-55%), with loss 
of p53 protective function, culminating with carcinoma development [see upper panel of 
Fig.2].25–27 However, other genes were found to be affected in Wnt, RTK-MAPK or PI3K, 
and TGF-β pathways in CRC. These include, respectively: AXIN2, FBXW7, ARID1A, 
FAM123B, SOX9, TCF7L2 and FZD10; ERBB2/3, IGF2, IGFR, NRAS, MEK, AKT, 
PIK3CA, PTEN and MTOR; and TGFBR1/2, ACVR2A/1B and SMAD2/3. Additionally, 
MYC, PTGS2 (COX-2), ATM and BAX were also shown to be important during CRC 
evolution.25 Mutations in DNA mismatch repair (MMR) genes MLH1, MSH2, and less 
significantly PMS2 and MSH6 are responsible for Lynch Syndrome. Moreover, 
hypermethylation of MLH1 is involved in ~15% of all sporadic CRC, leading to 
microsatellite instability. From the 138 driver genes identified (74 tumour suppressor 
genes and 64 oncogenes), only 2-8 are important for the development of a sporadic 
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CRC. The rest accounts for “passenger” alterations arising as aftereffect of the process. 
Transcriptional regulation, chromatin modification, STAT, Hedgehog, Notch and cell 
cycle/apoptosis complete the known list of pathways mutated by driver genes 
defects.19,28 However, further explanation and detailing of such cascades goes beyond 
the subject of this dissertation.  
 
Fig.2 - Genetic and epigenetic marks in three proposed pathways to sporadic CRC development. At the top: 
Fearon-Vogelstein diagram depicting key genes that are inactivated or activated upon mutation (less representative, 
inside parenthesis) and/or LOH (18q for DCC and SMAD2/4, and 17p for TP53); and their corresponding pathways (bold) 
found to be altered in CRC progression from normal epithelium to carcinoma, encompassing different phases of adenoma 
maturation. More recently, three pathways leading to CRC where proposed: traditional (50-70%), alternative (10-30%) 
and serrated (10-20%). Each is associated with a particular group of genetic and epigenetic alterations and polyp histology 
(respectively, tubular, villous and serrated). 
 
Amongst CRC classifications, one is commonly accepted and considers the 
existence of at least three molecular pathways conducting CRC pathogenesis coupled 
with genomic instability. Microsatellite instability (MSI; mostly hypermutated tumours), 
chromosomal instability (CIN; mostly non-hypermutated tumours), and CpG island 
methylator phenotype (CIMP; within both the hypermutated and non-hypermutated 
categories) differently affect tumour progression, metastization and treatment response. 
A particular etiology behind each pathway explains mutational status, immune response 
and other molecular disparities, contributing to a differential prognosis.19 
CIN, the most common pathway, is present in 70-85% of all sporadic CRC, and 
was also the first to be characterized. However, no consensual explanation for its origin 
has been yet reported. It may partly result from defects in chromosomal segregation, 
telomere stability, and DDR. CIN tumours frequently display imbalance in chromosome 
number (aneuploidy), sub-chromosomal genomic amplifications, loss of heterozygosity 
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(LOH), chromosome rearrangements, and base substitutions and deletions. Along with 
typical karyotypic abnormalities, a specific pattern of altered genes that drive oncogenic 
pathways is observed in CIN.19,29 However, it is not clear whether CIN arises from the 
evolution of such mutational status or vice-versa. The overall prevalence of genetic 
alterations in CIN follows the initial model, described here before, in line with CIN being 
observed in adenomas and increasing in tandem with tumour progression. Although 
disruption of APC has been proposed to establish a CIN phenotype, it is still 
controversial. Nonetheless, CIN was found to be correlated with most cell pathways 
altered in CRC.29 
 
Prognosis and treatment 
The 1-, 5- and 10-years relative survival rates for CRC are 83%, 65% and 58%, 
respectively. When detected at a localized stage, it is highly curable, with 5-year survival 
of 90%, in contrast with 70% when spread regionally or 13% in a metastatic stage.7 
Colon cancer treatment is greatly dependent on tumour stage. For stages 0 to III, 
and some cases of stage IV or recurrence, the primary approach is wide surgical 
resection of the lesion, including local excision or polypectomy. Adjuvant chemotherapy 
(CT) or radiotherapy (RT) are typically administrated to recurrence cases, stage III-IV 
patients, and stage II patients presenting any clinical high-risk features. CT includes 
several options, selected according to various factors such as tumour stage and clinical 
history/condition of the patient. Generally, 5-FU (5-Fluorouracil) is the basic approach, 
to which Leucovorin or a cytotoxic agent (often Irinotecan, Capecitabine or Oxaliplatin) 
are coadministered, potentiating 5-FU activity or treatment efficacy.30 Thus, available 
treatments include:  FOLFOX (Leucovorin, 5-FU, and Oxaliplatin), FOLFIRI (Leucovorin, 
5-FU, and Irinotecan), CapeOX (Capecitabine and Oxaliplatin) and FOLFOXIRI 
(FOLFOX plus Irinotecan). Biological agents targeting VEGF (Bevacizumab, Ziv-
aflibercept, or Ramucirumab) or EGFR (Cetuximab or Panitumumab) are usually added 
to one of the previous therapies, ameliorating the outcome. EGFR inhibitors are only 
applicable in tumours without KRAS mutations. Both RT and/or CT can also be used as 
neoadjuvant therapy when the tumour is difficult/impossible to resect, as it happens in 
most stage IV or recurrence cases. Ablation or embolization techniques might also be 
an option to treat some metastasis or recurrent liver tumours. Rectal cancers, more 
prone to local recurrence, present a somewhat different treatment, in which neoadjuvant 
RT/CT is also proposed for most stage III and some stage II cases.31–33 
 
Table 1 - TNM staging system for CRC along with corresponding criteria and anatomical stage (AJCC stage).33,34 
Primary tumour (T) 
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COLORECTAL CANCER EPIGENETICS 
General aspects, and chromatin and histone modifications 
Over the last fifteen years, attention has been driven to epigenetic in detriment of 
genetic changes. Currently, epigenetics is defined as heritable and possibly reversible 
alterations in the phenotypic expression of the genome, modifying gene expression 
without affecting DNA sequence, and encompasses: DNA methylation, histone 
modifications, chromatin remodelers and noncoding RNAs (ncRNAs).10 Knudson’s “two-
hit hypothesis” initially referred to gene mutations, both germline or somatic, has been 
reformulated to include epigenetic changes. However, it still accurately applies to CRC. 
Remarkably, it appears that most genes are aberrantly methylated rather than mutated 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades through the muscularis propria into the pericolorectal tissues (Rectal cancer: T3a <1 mm, T3b 1–5 mm, T3c 5–15 mm, T3d 15+ mm)33 
T4a Tumour penetrates into the surface of the visceral peritoneum 
T4b Tumour directly invades or is adherent to other organs or structures 
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in one to three regional lymph nodes 
N1a Metastasis in one regional lymph node 
N1b Metastasis in two to three regional lymph nodes 
N1c Tumour satellite deposits in 	subserosa or in non peritonealised tissues 
N2 Metastasis in ≥4 regional lymph nodes (a: 4–6, b: ≥7) 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Metastasis in one organ/site (for example liver, lung, ovary, nonregional node) 
M1b Metastasis in more than one organ/site or the peritoneum 
Stage grouping 
0 Tis N0 M0 
I T1-2 N0 M0 
IIA T3 N0 M0 
IIB T4a N0 M0 
IIC T4b N0 M0 
IIIA T1-2 (T2) N1/1c (N2a) M0 
IIIB T3-4a (T2-3) (T1-2) N1/1c (N2a) (N2b) M0 
IIIC T4a (T3-4a) (T4b) N2a (N2b) (N1-2) M0 
IVA Any T Any N M1a 
IVB Any T Any N M1b 
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in the average colon cancer genome. For many of those genes aberrant methylation is 
the only silencing mechanism observed.35,36 Epigenetics was introduced by CH 
Waddington in 193937, and its association with CRC was first discovered in 198338. Since 
then, it has been recognized that genetic and epigenetic aberrations are both part of a 
complex network that predispose to/trigger the development of each other, leading to 
CRC development.39,40 
Genomic DNA in eukaryotic cells is packed with specific proteins constituting 
chromatin. The repeating unit of chromatin is the nucleosome, which is formed by 
wrapping a two-turn “superhelix”, ~145–147 bp, of DNA around a histone octamer core 
(two copies of each histone H2A, H2B, H3 and H4). Besides histones, many other 
proteins integrate and manipulate chromatin structure.41	 Chromatin-remodelling 
complexes, through ATP consumption, adjust nucleosomal architecture by mobilizing 
(insertion/removal) nucleosomes, altering the configuration of nucleosomal DNA and 
histone-octamers, and recruiting other auxiliary proteins. Once formed, large scaffolds 
regulate many transcription factors.40,42–44 Based on studies with mouse models and cell 
lines, some members of the chromatin-remodelling machinery, such as histone 
acetyltransferase (HAT) Tip60, ATPase p400 and nucleosome remodelling and histone 
deacetylase (NuRD), modulate the functionality of Wnt-cascade. Moreover, SWI/SNF 
complex is also commonly altered in CRC by inactivation upon mutation of ARID1A and 
SMARCC2, and promotes metastasis upon mutation of BRG1.45  
Chromatin state is another important “tuner” of gene expression, existing in a 
condensed inactive state (heterochromatin) or in a noncondensed and transcriptionally 
active state (euchromatin). Some residues (mainly lysine and arginine) in the amino-
terminal tails of histones, that project from the nucleosome, are prone to certain post 
translational modifications, namely acetylation, methylation, phosphorylation, 
ubiquitylation, summoylation, ADP ribosylation, deamination and proline isomerization.44 
So far, methylation and acetylation are the two most explored and well-known. Di- and 
tri-methylation of H3K4 (H3K4me2 or H3K4me3), and acetylation at H3/H4 (H3K9Ac and 
H4K9Ac) are associated with an active state, opposingly to histone hypoacetylation and 
tri-methylation at H3K9 (H3K9me3) or H3K27 (H3K27me3), which are considered to be 
repressive marks. “Histone code” variations mediate silencing of tumour suppressor 
genes and activation of oncogenes, occurring after alterations in the expression and 
enzymatic activity of HATs and histone methyltransferases (HMTs) or histone 
deacetylases (HDACs) and histone demethylases (HDMTs).46 HDAC1–3, 5, and HDAC7 
are upregulated in CRC – at early stages of the disease, in the case of HDAC2.47 
Together with class III, these class I HDACs are implicated in the downregulation of 
tumour suppressor genes such as caudal type homeobox-1 (CDX1), in the Wnt 
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pathway.48 Lysine specific demethylase 1 (LSD1) is a HDMT, which demethylates H3K4 
and H3K9 and has been positively correlated with TNM stage, lymph node infiltration 
and metastatic disease in CRC patients.49 Moreover, two multimeric polycomb 
repressive complexes (PRCs), PRC1 and PRC2, are transcendent epigenetic regulators 
that are able to silence genes either independently or synergistically through its histone 
methylation capacity, initiating and maintaining H3K27me2/3, respectively. Also, EZH2 
(PRC1 component) and BMI1 are frequently overexpressed in CRC. The former predicts 
better recurrence-free survival (RFS) in those patients.45,50 
 
MicroRNAs 
From the two thirds of transcripts at some point transcribed from the mammalian 
genome only <2% codify any protein, the rest representing noncoding RNA molecules 
erroneously believed to present no function.51 MicroRNAs (miRNA, miR) are short RNA 
molecules (19–25 ribonucleotides) that mediate posttranscriptional gene repression or 
mRNA degradation of target mRNAs, while within RNA-induced silencing complex 
(RISC).52 miRNAs are the most widely studied class of ncRNAs, and translationally 
control over 60% of protein-coding genes. However, expression of ncRNAs is itself 
regulated by numerous proteins, DNA methylation and histone modifications, evidencing 
a highly complex network of interactions, which are often deregulated in cancer.53 In fact, 
many studies found hundreds of differently expressed miRNAs in CRC, and particularly 
connected with every important pathway of the multistep conventional CRC 
carcinogenesis.54 Both miRNA122a and miR135a/b downregulate expression levels and 
activity of APC and MSH2, mediating adenoma formation. let-7 miRNA family, miR-18a, 
-96 and -143 regulate expression of KRAS, while miR-21 and miR-126 are associated 
with PI3K pathway. Together with miRNAs regulating c-MYC (miR-17, -18a, -19a/b, -
20a, and -92a), they all play significant roles in an early to advanced adenoma 
transition.55 Additional altered miRNAs are implied in pre-malignant to malignant 
transformation (p53 regulators miR-16, -143 and -145, and downstream target miR-34a) 
or invasion/metastatic phenotype (miR-21, -625, -200 and -126). Moreover, 
downregulation of miR-378 and upregulation of miR-127-3p, -92a and -486-3p are 
associated with KRAS mutations, while upregulation of miR-31 is instead associated with 
BRAF mutations.46,54,55 
 
LONG NONCODING RNAS & DNA REPAIR 
LncRNAs involved in colorectal cancer development 
LncRNAs are simply defined as a class of ncRNAs transcripts longer than 200 nt 
and the most representative group among those, usually with no significant open-reading 
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frames (ORFs) in its sequence.56,57 These poorly conserved RNA molecules present 
tissue/cell, disease and spatiotemporal specificity, which supports their superior 
applicability as potential biomarkers and treatment-target molecules.57,58 Due to their 
inherent proneness to mutations, and hence structural diversity, fast evolutionary 
changes come easier to lncRNAs. In line with this, it is not surprising the existence of so 
many different functions and classifications attributed to these molecules. They are now 
thought to rival the impact of coding-transcripts, being involved in the regulation of most 
cellular mechanisms.59 
lncRNAs classification is diverse and an ever-changing task. The most varied 
classification is based on their function. Genes, proteins, mRNAs, microRNAs are all 
targets of regulation by lncRNAs. By interacting with specific proteins, lncRNAs can 
either repress, activate, recruit or serve as a scaffold for the assemble of protein 
complexes involved in transcription. A common way for lncRNAs to control transcription 
is through chromatin-based gene regulation.60 Indeed, several lncRNAs have been 
shown to interact with histone modifiers and chromatin remodelling complexes histone 
methyltranferases, such as PRCs and G9a protein.61 Although the main regulatory 
effects of lncRNAs occur in a pre-translational manner, they are capable of regulating all 
processes from gene to protein by different mechanisms. Additionally, lncRNAs are able 
to originate miRNAs and snoRNAs, act as molecular decoys or compete for common 
binding sites.62 
Overall, and particularly in CRC, lncRNAs have successfully helped to clarify 
previously unexplainable questions.63,64 Many arrays spotted a differential expression of 
numerous lncRNAs between normal and transformed mucosa; according to CRC 
development, invasion and metastatic stage63,65; and also in response to treatment, such 
as 5-FU66 and radiation67. Additionally, profiles include p53-related68 and MYC repressed 
transcripts69, as weel as hypermethylation of genes coding for lncRNAs70. CRC-
associated transcript 1(CCAT1) is upregulated in pre-malignant conditions and all 
disease stages in CRC, but not in normal tissues. Therefore, this MYC-regulated lncRNA 
has potential to be used for CRC screening, diagnosis, staging and development of novel 
therapies.71,72 Another CRC-associated lncRNA, from the same family, is CCAT2, which 
is also upregulated only in CRC – involved in cancer progression by promoting its 
invasion and metastasis. Also, CCAT2 is correlated with microsatellite stable cancers, 
higher expression levels of MYC and potentiation of Wnt signalling pathway.65,73 CCAT1-
L (CCAT1, the long isoform) upregulation in CRC mediates chromatin looping between 
the MYC promoter and its enhancers in coordination with CCCTC-binding factor 
(CTCF).74 Colorectal neoplasia differentially expressed (CRNDE) is detected in early 
adenomas but not in normal mucosa, fostering cell proliferation, migration and invasion. 
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CRNDE promotes Warbug effect and is upregulated in plasma of CRC patients, possibly 
being highly valuable for an early diagnosis.63,75 However, many additional lncRNAs are 
non-specific to CRC and they include transcripts differently expressed also in other 
malignancies.65 As the number of lncRNAs altered in CRC keeps increasing, the 
comprehension of the related molecular mechanisms is not parallelly evolving, and only 
a small group of transcripts is currently better studied.64 Little of them are implied in early 
detection of CRC and fewer in its risk assessment. Nonetheless, lncRNAs often play an 
important role in CRC progression, mainly through local invasion and distant metastasis, 
which renders them important prognostic biomarkers and treatment options.65,72 Their 
underlying mechanisms, expression patterns and functions are described in Table 2. 
 
Table 2 - List of some of the most representative and studied lncRNAs in CRC and associated mechanisms so 
far described in CRC and other diseases, expression patterns and functions in CRC development. 
lncRNA Mechanism Expression Function Ref. 
H19 Act as ceRNA for miR-138 and miR-200a; precursor of the RB-inhibitor miR-675. Up or LOI Progression 
76–78 
HOTAIR 
Recruitment of PCR2 and LSD1 complexes to HOXD, 
silencing HOXD. By supressing SETD2, impairs 
mismatch repair pathway. 
Up Progression Metastasis 
65,79 
MALAT1 
Binds to SFPQ and releases PTBP2; involved in RNA 
splicing and small RNA production; promotes cell 
migration, invasion, and metastasis. 
Up 
Early 
Diagnosis 
Progression 
Metastasis 
63,80,81 
HULC Binds to miR-372, and mediates cell invasion and metastasis to the liver. Up 
Progression 
Metastasis 
72,82 
PVT1 Downregulates Caspase3 and Smad4. Up Progression 83 
MYLKP1 Binds MYLK, increasing cell proliferation. Up Progression 84 
PCAT-1 By supressing BRCA2, impairs homologous recombination and, therefore, DNA repair. Up Progression 
85,86 
MEG3 By supressing MDM2, promotes P53 expression, and inhibits tumour growth. Down Progression 
72,87 
LET Regulates hypoxia signalling Down Progression 88 
TUSC7 Association with P53 and inhibition of miR-211, inhibiting tumour growth. Down 
Progression 
Metastasis 
72,89 
lincRNA-
p21 
Activated upon DDR by P53, directing P53 to its 
targets; increases sensitivity to radiation by targeting 
Wnt/β-catenin. 
Down Progression 65,90 
PTENP1 Binds to specific miRNAs and PTEN. Down Progression 91 
GAS5 Targets GR, inducing apoptosis. Down Progression 92 
BRCA2, breast cancer 2; ceRNA, competing-endogenous RNA; GAS5, growth arrest specific 5; GR, 
glucocorticoid receptor; HOTAIR, HOX transcript antisense RNA; HOXD, Homeobox D cluster; HULC, highly 
upregulated in liver cancer; LET, low expression in tumour;  lincRNA, long intergenic noncoding RNA; LSD1, 
lysine‑specific demethylase 1; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MDM2, 
mouse double minute 2; MEG3, maternally-expressed gene 3; MYLKP1, myosin light chain kinase 
pseudogene 1; PCAT-1, prostate cancer-associated transcript 1; PRC2, polycomb repressive complex 2;  
PTBP2, polypyrimidine tract binding protein 2; PTENP1, phosphatase and tensin homolog pseudogene 1; 
PVT1, plasmacytoma variant translocation 1; SFPQ, splicing factor proline/glutamine-rich; TUSC7, tumour 
suppressor candidate 7. 
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LncRNAs involved in DNA repair 
Tens of thousands of DNA lesions that each cell experiences per day would 
immediately lead to its death if no mechanism of repair was present. DNA damage 
response (DDR) is a broad term that includes different molecular responses responsible 
for DNA integrity maintenance, and includes DNA damage recognition, recruiting of 
mediators, transducers and effectors, culminating in DNA damage repair, activation of 
cell cycle checkpoints or even apoptosis.93,94 DNA repair is promptly ignited after the 
injury, but it is also highly regulated during the whole process, trying to avoid the ultimate 
fate: apoptosis. Evolution has been whittling a limited set of mechanisms, each 
responsible for repairing one or few specific DNA detrimental alterations.94 Double-strand 
breaks (DSBs) are the less frequent and most toxic DNA lesions, being commonly a 
consequence of exposure to UV radiation. DSBs repair is a difficult task for the cell and 
consists of two different main pathways: non-homologous end-joining (NHEJ) and 
homologous recombination (HR).93,95 Despite of so scarce examples, DSBs repair largely 
represents the most studied repair mechanism in light of lncRNAs. DSBs repair-related 
transcripts include PCAT-185, HOTAIR96, lncRNA-JADE97, DNA damage-sensitive RNA 
1 (DDSR1)98, transcribed in the opposite direction of RAD51 (TODRA)99, antisense 
ncRNA in the INK4 locus (ANRIL)100, or natural antisense transcript of Bok (BOKAS)101.  
The number of lncRNAs simultaneously associated with DNA repair and CRC is 
even smaller. DDSR1 was found to be upregulated in different cell lines including colon 
cancer cell line HCT116, and regulates early to late phases of DSBs repair response, 
starting to mediate the sequester of BRCA1-RAP80 complex away from DNA damage 
site, favouring HR. Upon induction by ATM-NF-κB, DDSR1 also mediates repression of 
p53 targets, and, at a later stage, greater levels of DDSR1 sequester hnRNPUL1.98 Both 
PCAT-1 and HOTAIR are upregulated in CRC, but their DNA-repair associated 
mechanisms have not been only described specifically for CRC. While PCAT-1 post-
transcriptionally binds to the BRCA2 mRNA 3ʹUTR, supressing HR pathway85, HOTAIR 
represses SETD2 by inhibiting the recruitment of the transcriptional machinery to SETD2 
promoter, which reduces H3K36 methylation and consequent recruitment of MSH6-
MSH2 protein heterodimer, culminating with impaired MMR [Fig.3].102 This pathway is 
responsible for identifying and excising single-base mismatches and insertion/deletion 
loops (IDLs), and is intimately connected with CRC.103 A defective MMR response leads 
to the accumulation of DNA errors throughout the genome, more frequently in short 
sequences of nucleotide repeats, more prone to these errors, called microsatellites. MSI 
is responsible for approximately 15-20% of all CRC cases.104 Tumours with high levels 
of microsatellite instability (MSI-H)/unstable are defined as having ≥30% instable loci, 
through a reference panel of 5 to 10 microsatellite loci, in opposition to tumours with low 
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levels of microsatellite instability (MSI-L) or microsatellite stable (MSS).105 MSI-H 
phenotype is characterized by a proximal location, poor differentiation, mucinous 
histology, and dense lymphocytic infiltration, compared to the conventional CIN pathway. 
Loss of protein expression of 4 MMR genes (MLH1, MSH2, MSH6, and PMS2) is a test 
often verified through immunohistochemistry (IHC) in clinical care. Indeed, MSI-H is a 
CRC biomarker with prognosis and treatment prediction value. MSI-H, as hypermutated 
tumours progress at a faster pace to malignancy, and usually do not respond to 5-FU 
treatment. Moreover, over 40% of MSI-H tumours present mutation of BRAF (V600E). 
Overall, however, MSI-H tumours present a better long-term prognosis.19,106 
 
Fig.3 - Model for DNA repair regulation in CRC by lncRNAs DDSR1, PCAT-1 and HOTAIR. Left panel: DDSR1 
initially mediates the sequester of BRCA1-RAP80 complex away from the DSB site, favouring HR (1). Upon induction by 
ATM-NF-κB, DDSR1 also represses p53 targets (2), and at later stages, greater levels of DDSR1 sequester hnRNPUL1 
(3). Middle panel: Upon DSBs, the assembly of RAD51 pre-synaptic filament is accomplished by BRCA1-PALB2-BRCA2 
complex. However, PCAT-1 interacts with BRCA2 mRNA inhibiting its transcription and subsequent HR repair. PCAT-1 
was shown to be repressed by PRC2-mediated epigenetic silencing. Right panel: HOTAIR inhibits transcription and 
phosphorylation (activation) of SETD2, reducing H3K36 methylation and consequent recruitment of MSH6-MSH2 protein 
heterodimer, impairing MMR. 
 
In contrast with genetic or epigenetic defects in MMR, base or nucleotide excision 
repair pathways (BER and NER, respectively) are largely understudied in CRC. Besides 
germline inactivation of BER gene MUTYH (responsible for MAP)24, no other noteworthy 
pathological mutations have been described for BER or NER.1 However, methyl-CpG-
binding domain protein 4 (MBD4)107, O6-methylguanine DNA methyltransferase 
(MGMT)108 and nei endonuclease VIII-like 1 (NEIL1)109 have been recently described as 
targets of promoter aberrant methylation in CRC. Furthermore, polymorphisms in many 
BER genes (APEX1,	XRCC1, PARP, LIG3, hOGG1, and EXO1) have been linked to 
CRC risk.110,111 BER is the main pathway repairing spontaneous, alkylating, and oxidative 
small non-helix-distorting chemical lesions of DNA bases112, while bulkier helix-distorting 
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and more complex lesions, such as pyrimidine dimers and intra-strand crosslinks, are 
corrected by NER.113 BER also removes uracil (or its analogues) misincorporated into 
the DNA as a result of 5-FU, further linking DNA repair and CRC sensitivity to 
treatment.114 Through a functional analysis of the overall DNA repair capacity (DRC) for 
BER and NER in a subset of CRC patients, as well as genetic and epigenetic aspects, 
Slyskova et al (2012) found no meaningful alterations, indicating that excision repair is 
not a major driving factor in malignant transformation, which is consistent with previous 
studies.1 
 
CpG ISLAND METHYLATOR PHENOTYPE (CIMP) & PROGNOSIS 
DNA methylation 
DNA methylation represents the most studied epigenetic area in CRC.115 In fact, 
the first epigenetic alteration reported in cancer was global loss of DNA methylation, 
represented by 5’-methylcytosine (5-mC), in CRC, and affecting mostly repetitive 
transposable sequences, such as LINE-1 and Alu elements.36,38 This is an age-
dependent and early event in CRC development, predisposing to genomic instability, 
including loss of imprinting (LOI) and CIN. Accordingly, LINE-1 hypomethylation 
inversely associates with MSI and/or CIMP.115 DNA methylation occurs at cytosine bases 
preceding guanines, called CpG dinucleotides (C-phosphodiester-G bond), most of 
which are methylated in a healthy state. However, there are also unmethylated CpG rich 
sequences, called CpG islands, and generally located in the 5’ region of approximately 
half of all human gene promoters. CpG islands are 200-2000 bps long, with a CG content 
>50% and a ratio of observed to expected CpGs >60%, and are involved in the regulation 
of gene expression.54,115,116 When methylated they may induce chromatin conformational 
changes, through MBD proteins, hindering promoter assessment and repressing 
transcription. In CRC, both hypermethylation and hypomethylation abnormalities are 
present, but in a reversed pattern from normal mucosa.46  
The addition of a methyl group (-CH3) to a cytosine is catalysed by DNA 
methyltransferases (DNMTs) using S-adenosylmethione as the methyl donor compound, 
in either a de novo (DNMT3A and DNMT3B) or maintenance fashion (DNMT1).36,46 In 
CRC, both DNMT1 and DNMT3B were shown to contribute to CpG methylation and 
aberrant gene silencing. Moreover, mutations in DNMT1 and SNPs in DNMT3B have 
also been linked with CRC risk.10,39 
 
CIMP involvement in colorectal cancer 
It has been increasingly recognized that a distinct methylation pattern appears as 
a “function of age”, the so-called “epigenetic drift”, which also affects methylation of 
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promoters.115 Throughout the rest of this text the term “methylation” will be applied in the 
sense of gene promoter hypermethylation unless otherwise stated. DNA methylation in 
both normal-appearing mucosa and CRCs (age-related methylation, type A methylated 
genes) may precede tumour formation, arising in close relation with epigenetic 
microenvironment and external factors, whilst DNA methylation specifically in CRCs 
(cancer-specific methylation, type C methylated genes) seems to be a less random 
process, and is associated with a more limited number of genes and a subset of CRCs 
– which then evolve along a CIMP pathway.117 The molecular causes underlying such 
methylation are not well-understood, but there are multiple models for cancer-related 
aberrant methylation, encompassing mechanisms such as overexpressed, hyperactive, 
or misdirected DNMTs, dysregulation of associated ncRNAs, unrepaired halogenated 
DNA damage products mimicking 5-mC, and impaired barrier elements.36  
Hundreds to thousands of genes are aberrantly methylated in the average CRC 
genome, and although no sharp distinction between type A and type C genes has been 
made, many of the CRC-specific hypermethylation events have been linked to the same 
important pathways targeted by mutational events.36,39,54 The term “CpG island 
methylator phenotype,” or CIMP, was first coined in 1999 by Toyota, with Baylin, Issa 
and others to characterize some tumours presenting a distinct phenotype of 
simultaneous and intense promoter hypermethylation of some tumour suppressor genes, 
leading to progressive genetic silencing and tumourigenesis, even in the absence of any 
genetic mutations. According to the same study, CRCs can be divided in CIMP− (CIMP-
negative) or CIMP+ (CIMP-positive), respectively displaying rare methylation or 
simultaneous aberrant methylation of several genes.117 One of the first and best studied 
alterations was biallelic promoter CpG island methylation of MLH1, which unveiled a 
strong link between CIMP and MSI-H tumours.39 Indeed, CIMP+ tumours have been not 
only associated with MSI-H phenotype, but also with older age, female sex, mucinous 
cell differentiation, smoking, BRAF and less often KRAS mutations.39 Approximately 20% 
of CRCs are CIMP tumours36,118, rarely occurring in rectal cancer and increasing linearly 
up to the ascending colon.119  
To define CIMP, promoter methylation of a panel of specific genes is evaluated, 
with some of them being more valuable than others. However, which specific methylated 
loci should be used to describe CIMP is not standardized.54,120 The so-called “classic” 
panel of Park et al., later described by Issa117, comprises CpG islands in MLH1, 
CDKN2A(p16), and methylated in tumours (MINTs) 1, 2, and 31 loci, and provides a 
simplified and representative approach to define CIMP. The five methylation markers 
have distinct functions. MINT markers correspond to the promoters of unique genes 
except MINT2; MINT1 corresponds to synaptic vesicle glycoprotein 2C gene (SV2C), 
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and MINT31 corresponds to a CpG island upstream of the calcium channel CACNA1G 
gene.121,122 P16 is an inhibitor of cyclin-dependent kinase 4 (CDK4) and CDK6, which is 
associated with aging and functions as a tumour suppressor, leading to unrestrained cell 
proliferation upon genetic or epigenetic inactivation.123 In Park’s work, the selected 
technique to analyse methylation was methylation-specific PCR (MSP).124 These 5 
genes/loci were tested first in 1999 by Toyota et al. along with other 25 newly cloned 
differentially methylated DNA sequences, and were later selected based on their 
frequent methylation.117,124 In 2006, using MethyLight technology, Weisenberger et al. 
proposed a new robust 5-gene panel (CACNA1G, IGF2, NEUROG1, RUNX3, and 
SOCS1), further supporting CIMP as a distinct molecular trait of CRC.125 Nevertheless, 
it does not seem to outperform the “classic” one.116 Both studies classified tumours as 
CIMP+ when more than 1 marker was methylated. The dichotomized CIMP classification 
adopted in those articles, while being the first defined and the most common, is not the 
most informative. This bimodal distribution failed to explain CIMP+/MSS tumours for 
example, which were then shown to be better clarified in a tri-modal partition of CIMP-
High (H), CIMP-Low (L) and CIMP-0.116,118,126,127 In fact, Ogino et al. quantified DNA 
methylation (MethyLight) also in 5 CIMP-specific gene promoters (CACNA1G, 
CDKN2A(p16), CRABP1, MLH1, and NEUROG1), defining tumours presenting 4-5/5 
methylated markers as CIMP-H, 1-3/5 methylated markers as CIMP-L, and 0/5 
methylated markers as CIMP-0 tumours.127 Using another large cohort, the same author 
tested the prior markers plus IGF2, RUNX3, and SOCS1 to classify CRC as CIMP-H 
when 6-8/8 markers were methylated, CIMP-L when only 1-5/8 were methylated, and 
CIMP-0 if no promoter was found to be methylated.128 Moreover, both “classic” and “new” 
panels have also been applied in a tri-model classification, and they may be further 
developed to contain additional loci.118 
The characteristics of the three CIMP groups are not well defined, but they do 
present independent associated features. Regardless of MSI status, CIMP-H tumours 
correlate with proximal tumour location, serrated pathway, older age, female gender, 
poor differentiation,	signet ring cells, high BRAF and low TP53 mutation rates, loss of 
nuclear p27 (CDKN1B), LINE-1 methylation, inactive CTNNB1 and PTGS2, and 
expression of DNMT3B, p21 (CDKN1A), TGFBR2 and SIRT1.11,120 CIMP-H represents 
~15-20% of all CIMP tumours, and although it is more related to MSI-H, both MSI-H 
CIMP-H and MSI-L/MSS CIMP-H tumours exist.120 CIMP-L tumours are usually MSS or 
MSI-L, characterized by CIN, and associated with male gender and KRAS mutations. In 
fact, KRAS and BRAF mutations are mutually exclusive and seem to play an important, 
yet still unclarified, role in CIMP development.46 By its turn, CIMP-0 tumours are 
associated with CIN, wild-type KRAS/BRAF, distal colon and show no sex predilection.120 
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Furthermore, CIMP-negative tumours have been occasionally split into two different 
subtypes, one associated with TP53 mutations and distal location, and the other one 
showing a low frequency of hypermethylation or cancer-specific gene mutation, while 
mostly located in the rectum.46  
Distinctive molecular subclasses of MSI/CIMP tumours have been proposed 
when classifying CRCs. However, because of subtle differences between CIMP-L and 
CIMP-0 or MSI-L and MSS, only 6 groups are comfortably distinguished. The main 
disparities described between MSI-H CIMP-H (10%) and MSI-L/MSS CIMP-H (5-10%) 
tumours are MLH1 promoter methylation (MSI-H CIMP-H) and their respective 
association with good or poor prognosis. MSI-H CIMP-L/0 (5%) includes mainly Lynch 
syndrome, but also sporadic CRC. Unlike MSI-L CIMP-L tumours (~5%), this subtype is 
preferably located in proximal colon and is not correlated with MGMT methylation and 
loss. In addition, MGMT methylation is also the main difference between MSI-L CIMP-L 
and MSS CIMP-L (30-35%) tumours. The characteristics of the remaining and biggest 
group, MSI-L/MSS CIMP-0 (40%), greatly overlap with those described above in light of 
the first CIMP-negative group [Fig.4].120 
 
Molecular pathways according to genetic and epigenetic aspects 
The statement that epigenetic changes take place at early stages of adenoma 
formation inspired the division of sporadic CRC formation into three pathways, firstly by 
Issa and later by Coppedè.46,129 The majority of sporadic CRCs originate in conventional 
villous and/or tubular adenomas, following the classic adenoma-carcinoma sequence130, 
and are further divided according to its association with KRAS (alternative pathway) or 
APC (most traditional pathway) mutations and CIMP-L or CIMP-0, respectively. Common 
features between them include CIN, MSI-L/MSS status and TP53 mutations (specifically 
in the distal colon, for the KRAS-mutated pathway).46 Moreover, while the APC-mutated 
pathway is the most typical (50-70%), the KRAS-mutated pathway (10-30%) is correlated 
with poor prognosis and unresponsiveness to 5-FU and Cetuximab.46,129 More recently, 
another new “alternative” to the conventional adenoma-CRC pathway with unique 
features has been described (10-20%), involving instead serrated polyps as the 
precursor lesion and evolving through suppressive methylation of many key genes. This 
is the route through which many CIMP tumours arise, and is also associated with BRAF 
and KRAS mutations (but not APC or CTNNB1), proximal location, and MSI 
[Fig.2].46,115,129 Importantly, CIN, MSI and CIMP are not mutually exclusive. Indeed, up to 
25% of MSI and 33% of CIMP+ tumours can exhibit chromosomal abnormalities, while 
most MSI/CIN– CRCs are also CIMP+, and up to 12% of CIN+ tumours are MSI-H 
[Fig.4].131–133 
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Fig.4 - Estimated distribution of CIN, CIMP and MSI subtypes, and a six-group classification according to MSI and 
CIMP status in CRC. CIN is the most common subtype in CRCs (circle shape, 70-85%), followed by MSI (dashed triangle, 
~15-20%) and CIMP (dotted triangle, ~20%). However, these frequencies are still a controversial topic. Some CIMP 
tumours (mostly CIMP-L) also display a CIN phenotype, while most CIMP-H tumours are also microsatellite instable. 
Moreover, a reduced number of tumours may present both chromosomal and microsatellite instability. Ogino and Goel 
(2008) also proposed a classification of CRC according to MSI/CIMP status into six groups, albeit three of them are not 
well-defined. (Right panel was adapted120). 
  
Methods of DNA methylation analysis 
The heterogeneity in CIMP-related studies goes far beyond the panel and the 
threshold selected. Besides the different clinical characteristics of the population 
(including clinical stage, treatment and location of the tumour), specimen preservation 
(either cryopreservated or formalin fixed paraffin embedded) and laboratory methods to 
assess gene methylation greatly varies between studies. MSP and MethyLight are the 
two most preferred techniques, followed by bisulfite pyrosequencing and combined 
bisulfite restriction analysis (COBRA).118 MSP is a rapid and cost-effective qualitative 
method of analysis that uses bisulfite-modified DNA as a template for PCR amplification 
with two primer sets – specific for methylated (MSP) and unmethylated (classical PCR) 
sequences. Quantitative variations of this technique based on real-time PCR include 
detection through an intercalated dye like SYBR® Green or by a TaqMan® probe 
(MethyLight). These high-throughput, specific and sensitive assays determine the level 
of methylation upon normalization of the signal usually to an Alu- or β-actin-based control 
reaction.134,135  
DNA methylation as diagnostic biomarker 
(Biological) biomarkers have been classically defined as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological and pathological 
processes, or pharmacologic responses to a therapeutic intervention”.136 An ever-
increasing number of studies have demonstrated the potential for using methylated DNA 
as biomarker for the early detection of CRC and, less representatively, its application as 
a prognostic or predictive biomarker.137 Robust and reliable non-invasive biomarker 
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assays for the detection of early CRC are needed, as currently it represents the most 
effective strategy to reduce mortality. In fact, somatic mutations are relatively rare 
compared to DNA methylation alterations in the early stages of CRC tumourigenesis.115 
Both blood- or stool-based biomarkers have been proposed. Commercially available 
tests include FDA approved analysis of Vimentin (VIM) gene methylation (ColoSure™) 
and plasma-based test of aberrantly methylated Septin 9 gene (SEPT9), in Europe 
(EpiproColon® 1.0, ColoVantage® and RealTime mS9).115 Other methylated biomarkers 
in “circulating DNA” (ALX4, DAPK, NGFR, HPP1, NEUROG1, RUNX3 and TMEFF2), 
stool (ATM, BMP3, FBN1, GATA4/5, GSTP1, NDRG4, SFRP1 and TFPI2) or in both 
(APC, CDKN2A(p16), HLTF, MLH1, MGMT, RASSF2A, SFRP2 and WIF) were 
proposed for CRC screening.115,137,138 Moreover, methylated BMP3, methylated NDRG4, 
and mutant KRAS combined test (Cologuard®) was also FDA approved as a stool DNA-
based assay, and showed a greater overall sensitivity than FIT test for CRC or early 
adenoma detection.139 Notably, multitarget DNA tests and/or combination with 
conventional approaches are likely to improve the sensitivity to detect the lesion.140 
DNA Methylation and CIMP in prognosis and treatment 
Clinical decisions following prognosis in CRC are currently based on tumour 
staging and histopathologic characteristics – categories I and II of prognostic factors, 
respectively, according to the College of American Pathologists (CAP).115,141 However, 
such approach is fallible, as illustrated by numerous patients with the same stage, which 
progress differently, surviving shorter or longer periods. Selection of specific methylated 
DNA signatures seems to be highly feasible for the development of prognostic 
markers.115 Methylation of APC, CDKN2A(p14) or RASSF1A was associated with poor 
prognosis in a subset of patients independently of tumour stage or differentiation142, while 
HOPX and RET were correlated with worse prognosis of stage II and III CRC, 
respectively. Other genes whose aberrant methylation has been associated with poor 
prognosis include CDKN2A(p16), IGF2 and extracellular matrix remodelling pathway-
associated genes (IGFBP3, EVL, CD109 and FLNC).46 Methylation of HLTF and 
TMEFF2 in serum was independently associated with poor outcome.143 In opposition, 
methylation of MGMT or MLH1 was linked to a more favourable prognosis.142,144 
Moreover, methylation of genes targeted by the polycomb group of proteins (SFRP1, 
MYOD1, HIC1 and SLIT2) was also associated with good prognosis in CIMP– male 
patients.115 Because different pathways are commonly affected in CRC, selecting a panel 
of different biomarkers will potentiate the accuracy of the test. Therefore, among all 
biomarker candidates, CIMP status is by far the most promising indicator for 
prognosticating CRC patients in terms of phenotypic presentation, therapeutic response 
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and survival outcomes.115,145 CIMP+ tumours have been independently associated with 
shorter survival in many studies, irrespective of MSI status, particularly in patients with 
early and locally advanced CRC. Moreover, CIMP status was also shown to be a 
negative prognostic factor in patients with metastatic colorectal cancer treated with CT.146 
However, conflicting results have been reported as well, with some studies describing a 
null association between CIMP-H and CRC prognosis, or even noticing a better 
prognosis after CT.118,147 Since most of CIMP-H-related clinicopathological and 
molecular features overlap with those for MSI cancers, CIMP status is believed to 
influence the good prognosis of CRC that is attributed to MSI. Therefore, evaluation of 
both CIMP and MSI is highly recommended when stablishing prognosis.145 Additionally, 
such analysis has been proved to depend also on the specific location of the tumour.145 
Bae et al. found that CIMP+ tumours correlated with shorter disease-free survival (DFS) 
and overall survival (OS) in distally but not in proximally located tumours, while MSI was 
correlated with better survival only in proximal tumours.148 Given that most CIMP+ 
tumours present BRAF mutations, then CIMP biomarker is also predictive for mutational 
profile in CRCs.125 In fact, BRAF mutated CRCs may contribute to shorter survival time 
in CIMP+ MSS tumours.149 
Although plenty of studies have been evaluating the predictive value of CIMP in 
treatment response mainly to 5-FU, no solid conclusion has been reached. Some studies 
agreed that adjuvant CT conferred a DFS and OS benefit among CIMP+ stage II and III 
CRC patients, while others concluded to the contrary or found no significant predictive 
valour.118 Nonetheless, the administration of 5-FU to treat CIMP tumours is not currently 
recommended. One interesting study showed the benefits to stage III CIMP+ MSS 
patients after the addition of Irinotecan to 5-FU/Leucovorin therapy (FOLFIRI). CIMP was 
more strongly associated with a better response to the addition of Irinotecan than MMR 
status.150 
Besides being an appealing diagnostic, prognostic, and predictive biomarker, 
alterations of methylation status are also potential pharmacologic targets, as they are 
reversible, stable and early-in-development events. Agents inhibiting DNMTs and 
HDACs can be applied to reactivate epigenetically silenced tumour suppressors. DNA 
demethylating drugs 5-Azacitidine and 5-Aza-2′deoxycitidine (Decitabine), and HDAC 
inhibitors Vorinostat and Valproic acid are currently approved for the treatment of some 
malignancies. The combination of both groups of inhibitors has been suggested to be a 
better strategy due to a more synergistic effect, as well as its coadministration with 
chemotherapeutic drugs. Despite their low specificity and high toxicity, further preclinical 
investigations and several clinical trials, in order to establish the applicability of these 
and other related agents in CRC treatment.30,54   
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AIMS 
The overall aim of the present dissertation is the epigenetic characterization of 
sporadic CRC in light of lncRNAs (Project I) and DNA methylation (Project II), 
respectively in two independent population-based sets. Particularly, the first project 
encompassing the discovery of new transcripts altered in CRC and associated with DNA 
excision repair pathways, and the former focused on the analysis of promoter CpG 
islands hypermethylation pattern (CIMP tumours) and further determination of CIMP 
prognostic value.  
PROJECT I 
The objective of this work was primarily to stablish the expression profile of ninety 
disease-related lncRNAs in twenty tissue samples, which were equally divided into four 
groups according to being either healthy mucosa or CRC lesions, and presenting either 
lower or higher DNA repair capacity for BER DNA repair pathway; in order to find a 
possible role for lncRNAs in sporadic CRC tumourigenesis in association with BER 
functionality, and ultimately finding new biomarkers or treatment-targets. 
 
PROJECT II 
The main goal of this second project was the profiling of CIMP status in tissue 
samples from a subset of 211 CRC patients and 43 controls, by measuring the promoter 
methylation of the “classic panel” of five genes/loci, through real-time qMSP (SYBR® 
Green-based) with bisulfite converted DNA; and further study the possible association  
with other molecular and clinicopathological features and patients’ prognosis. 
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MATERIALS AND METHODS 
PROJECT I 
Study patients and sample collection 
The study included twenty tissue specimens isolated from seventeen patients 
with sporadic primary CRC who underwent surgical resection, selected from a previous 
subset of 70 patients included in Slyskova’s work.1 Patients were recruited between 2009 
and 2011 at the Thomayer Hospital (Prague, Czech Republic), the General University 
Hospital (Prague, Czech Republic), and Teaching Hospital and Medical School of 
Charles University (Pilsen, Czech Republic). All patients signed informed consent. Ethics 
approval was granted by the appropriate committees at the 3 hospitals. Tumour tissue 
and adjacent healthy colon/rectal tissue (5–10 cm distant from the tumour) were resected 
from all patients. All subjects were of the same ethnicity (Caucasian). Tumour and 
adjacent normal tissues were deep frozen immediately after extraction and stored at 
−80°C. 
Selection of samples and DNA repair assays 
From the 70 paired samples tested by Slyskova and colleagues, 30 samples (24 
paired, 3 CRC and 3 from normal mucosa) were selected based on RNA integrity number 
(RIN) (≳ 5) measured before, and available expression of BER genes and related DNA 
repair capacity data. The samples were then scored according to the values of BER-
DRC, and the median was calculated for each of the two groups of samples (CRC versus 
control). The five highest and lowest values were selected, allowing four groups to be 
formed, each with five samples, namely: CRC with higher BER-DRC, CRC with lower 
BER-DRC, healthy mucosa with higher BER-DRC and healthy mucosa with lower BER-
DRC. 
Although the determination of DRC values was not included in the present work, 
as it had been already performed, a brief and general explanation of the procedure will 
be next attended. Firstly, proteins were extracted from tissue	and protein concentration 
was measured by a Fluorescamine assay (Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany), with a NanoDrop® 3300 (Thermo Scientific, Wilmington, DE, USA). In vitro 
repair assays were adopted as previously described150 and implemented using a 12-gel 
slide format.105,151 Protein extracts were then incubated with substrate DNA from human 
PBMCs treated with Ro 19-8022 (Hoffmann-La Roche, Basel, Switzerland) for 5 min, 
and irradiated by a 500 W halogen lamp to induce 8-Oxoguanines, which are known to 
be repaired specifically by BER. Levels of DNA strand breaks, generated during removal 
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of lesions, reflect the repair activity of the extract. After pipetting each extract per agarose 
gel and the period of incubation, the protocol followed was the same as described before 
for the Comet Assay.153 Each extract was also incubated with DNA from untreated 
PBMCs to determine non-specific endonuclease activity of the extract. Finally, slides 
were stained with SYBR® Gold (Invitrogen, Carlsbad, CA, EUA), and comets were 
scored using a Nikon fluorescence microscope. DRC data were evaluated as tail DNA% 
(%T).1 
RNA extraction  
Total RNA was extracted from tissues using AllPrep™ DNA/RNA mini kit (Qiagen, 
Hilden, Germany) according to manufacturer’s instruction. Concentration and purity of 
all RNA samples were determined spectrophotometrically by measuring their optical 
density (A260/280>2.0; A260/230>1.8) using a NanoDrop® ND-2000c (Thermo 
Scientific, Wilmington, DE, USA). Additionally, RIN was checked using an Agilent 
Bioanalyzer 2100, with a RNA 6000 Nano LabChip® (Agilent Technologies, Palo Alto, 
CA, USA),  following the protocol provided. The quality of some RNA samples was assed 
by electrophoresis using 2.5% Ethidium Bromide (EtBr)-stained agarose gels instead. 
LncRNAs profiling 
The simultaneous expression of 90 lncRNAs, five housekeeping reference 
controls and one negative control was determined using the disease-related Human 
LncProfiler™ 96-well qPCR Array Kit (cDNA synthesis kit and qPCR array) according to 
the instructions of the manufacturers (System Biosciences, Mountain View, CA, USA). 
Each kit allows 20 profiles to be performed. Off mention, lncRNA cDNA synthesis 
reaction setup includes three different steps, namely polyadenylation, annealing of 
adaptor, and conversion to cDNA. The initial step greatly enhances cDNA synthesis 
yields of lncRNAs, potentiating the detection by qPCR. 5 µL of total RNA from each 
sample (diluted to ~200-400 ng/µL) were cDNA converted and next submitted to real-
time PCR. Briefly, reaction mixtures for each 96-well qPCR plate consisted of 1400 µL 
2X SYBR® Green PCR Master Mix (Applied Biosystem, Foster City, CA, USA.), 1400 
µL of RNase-free water (QIAGEN GmbH, Hilden, Germany) and 20 µL of cDNA. The kit 
provided primers in a plate, which were resuspended with 44 µL of RNase-free water 
(QIAGEN GmbH, Hilden, Germany) per well before being use. 2 µL of each primer pair 
and 28 µL of reaction mixture were loaded in each well of the qPCR plate. Thermal 
cycling conditions consisted of initial incubation at 50°C, a denaturation step of 95˚C for 
10 min, followed by 40 cycles of denaturation at 95˚C for 15 sec, and annealing and 
extension at 60˚C for 1 min. An additional dissociation stage was included (95°C for 15 
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seconds, 60°C for 15 seconds, followed by a slow ramp to 95°C). Real-time PCR 
analysis was performed with an Applied Biosystems® 7500 Real-Time PCR Sequence 
Detection System. Finally, the cycle number at which the reaction crossed a threshold 
(CT) was determined for each gene. Analysis of the RT-qPCR data was performed using 
SDS version 1.3.1 software (Applied Biosystem, Foster City, CA, USA) as previously 
described154. Raw CT data for each lncRNA was normalized to the geometric mean of 
the five control genes, per plate (ΔCT = CTlncRNA − CTcontrols). The relative expression 
levels of target lncRNAs were determined by the equation 2−∆CT. Fold change values 
were calculated between two groups of interest: 2-(∆ CTgroup of interest 1 – ∆CTgroup of interest 2). 
Statistical analysis 
Expression data from lncRNAs profiling were statistically evaluated using 
GraphPad prism software version 7.0. P-values of less than 0.05 were considered 
statistically significant. P-values were adjusted according to Holm-Šídák correction for 
multiple comparisons. 
 
PROJECT II 
Study patients and sample collection 
213 samples from sporadic and primary CRCs were obtained from a wide series 
of patients diagnosed and submitted to tumour removal surgery at the Portuguese 
Oncology Institute – Porto, Portugal, between November 1994 to March 2012, with no 
previous history of CRC. However, almost 92% of all patients studied were diagnosed 
between 2005 and 2012. All CRCs were extracted from primary tumours. Tissues were 
routinely fixed and paraffin-embedded for standard pathologic examination, allowing for 
tumour classification and World Health Organization (WHO)/American Joint Committee 
on Cancer (AJCC) grading and staging.155,156 Additionally, an independent set of 50 
paraffin-embedded normal colorectal mucosa from patients not diagnosed with CRC or 
IBD was used as control. Relevant clinical data were collected from clinical charts [see 
Results section – Table 7]. The study was approved by the institutional review board 
(CESIPOFG-EPE  120/015). 
DNA extraction from paraffinized tissues sections 
A representative paraffin block from each patient was selected and 12 serial 8-
micrometres thick sections were cut and placed on glass slides, from which two were 
H&E stained (initial and final slides). Next, an experienced pathologist delimited the area 
of tumour to be macrodissected, in the corresponding H&E stained slides.  Other six non-
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stained slides were deparaffinised using Xilol and Ethanol 100%, 90%, 70% and 50%, 
following initial incubation at 55 ºC for 30-60 min to melt paraffin. A disposable sterile 
scalpel blade was then used to macrodissect the selected tumour areas from the slides 
with the addition of some drops of digestion buffer (Tris-HCl 1M, EDTA 0.1M, Tween 20 
and sterile bi-distilled water (B.Braun, Melsungen, Germany)), by superposition to the 
proper H&E stained slide. The removed portions were subsequently placed in labelled 
1.5 mL tubes, with 1000 μL of digestion buffer plus Proteinase K (20 mg/mL, 25 μL) 
(Zymo Research Corp., Irvine, CA, USA), and left incubating at least overnight at 55ºC, 
until total digestion was accomplished. An extra 15 μL volume of Proteinase K was added 
to facilitate complete digestion of some samples.  
DNA was extracted from tissue according to the standard Phenol-Chloroform 
procedure157, using 500 μL of Phenol-Chloroform solution at pH 8 (Sigma-Aldrich and 
Merck KGaA, Darmstadt, Germany) in Phase Lock Gel Light tubes (5 Prime, Hamburg, 
Germany). After centrifuging the tubes for 15 min at 13 000 rpm, the upper aqueous 
phase containing DNA was transferred to a new tube, and then precipitated at -20ºC 
overnight using chilled Ethanol 100% (twice the volume of the aqueous phase) (Merck 
KGaA, Darmstadt, Germany), Ammonium Acetate 7.5 M (1/3 volume) (Sigma-Aldrich 
Chemie GmbH, Steinheim, Germany) and Glycogen (2 μL) (Ambion, Austin, TX, USA). 
This step was followed by two centrifugations at 13 000 rpm for 20 min with 70% Ethanol, 
and the pellets were then air dried and eluted with bi-distilled water (B.Braun, Melsungen, 
Germany). After DNA elution, concentrations were determined using NanoDrop™ Lite 
Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). 
Two of the total 213 sporadic CRC cases and seven control samples lacked 
enough material to be extracted, or re-extracted due to low amounts of DNA yielded. 
These were excluded from this work. The next procedures were conducted for the 
remaining 211 CRC cases and 43 controls. 
Bisulfite conversion 
First introduced by Frommer et al (1992), bisulfite conversion is the gold-standard 
technology for detection of DNA methylation; grounded on the finding that Sodium 
Bisulfite treatment of cytosine and 5-methylcytosine has different consequences, 
originating different DNA sequences for methylated and unmethylated DNA. In this 
regard, cytosines in single-stranded DNA are converted into uracil residues and 
recognized as thymine in subsequent PCR amplification and sequencing, while 5mCs 
are immune to this conversion and remain as cytosines allowing them to be distinguished 
from unmethylated cytosines. The procedure includes initial denaturation of DNA double-
strand, followed by sulfonation of unmethylated cytosines, giving origin to a cytosine 
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sulfonate, then deamination and finally desulfonation, thus losing the bisulfite group and, 
finally, becoming uracils. Converted DNA strands are no longer self-complementary, 
permitting the evaluation of DNA methylation along the DNA single strand (ssDNA).158,159 
The required volume of DNA to achieve the final quantity of 1000 ng of DNA was 
diluted in sterile double-distilled water to a total volume of 20 μL in a PCR tube, according 
to the specified concentration of each sample. Due to the low concentration of some 
samples, the quantity of DNA extracted from those samples was instead adjusted to 500 
ng, 600 ng or 750 ng, and equalized at the last step of the conversion procedure.  
DNA denaturation and bisulfite conversion were processed into one-step using 
the EZ DNA Methylation-Gold™ Kit (Zymo Research Corp., Irvine, CA, USA) according 
to manufacturer’s instructions. Briefly, 130 μL of the CT conversion reagent were added 
to 20 μL of each DNA sample tube. The samples were then transferred to a Veriti® 96-
Well Thermal Cycler (Applied Biosystems Inc, Foster City, CA, USA) running under the 
following steps: 98 ̊C for 10 min, 64 ̊C for 3 h, and storage at 4 ̊C. 600 μL of M-Binding 
Buffer were added to a Zymo-Spin IC™ column, followed by the samples, and after 10 
min the mixture was centrifuged at 10 000 rpm for 30 sec. Each column was washed 
using 100 μL of M-wash buffer, with a new centrifugation. 200 μL of M-Desulphonation 
buffer were then added and the plate was left at room temperature during 20 min, 
followed by another centrifugation. Two consecutive steps including washing (200 μL of 
M-wash Buffer) and centrifugation were performed. Each column was then transferred 
to a new tube and 30 μL of bi-distilled water were directly added to the centre of each 
column. 5 min later, the samples were centrifuged at 12 000 rpm for 30 sec to elute the 
DNA. This step was repeated with an additional 30 μL volume of double-distilled water, 
completing a total volume of 60 μL added. For those samples with lower amounts of 
DNA, the total elution volumes applied were respectively 30 μL, 36 μL and 45 μL. 
Universal Methylated Human DNA Standard (Zymo Research Corp., Irvine, CA, USA) 
was used as DNA methylation control, in which case 10 μL were used to prepare the 
initial dilution, and a total volume of 20 μL (10 μL + 10 μL) of bi-distilled water was added 
to elute DNA. 
Primers design and selection 
A subsequent PCR process is necessary to determine the methylation status of 
targeted loci by using specific methylation primers after the bisulfite treatment. Therefore, 
new primers specific for methylation were design using Methyl Primer Express® 
Software v1.0 (Applied Biosystems Inc. Foster City, CA, USA). After copying the specific 
gene/locus sequence from GenBank® (NCBI) to the program, the proper CpG island 
was selected, and suggested primer sequences were scored by the program.  According 
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to the characteristics of each primer pair analysed with NetPrimer (Premier BioSoft, Palo 
Alto, CA, USA), and the pretended location, one of the proposed pairs was selected per 
gene/locus. To design the new primers each gene/locus CpG islands were investigated 
first. The studies by Toyota and colleagues (1999)117,160 and Kondo et al (2003)161 were 
used as reference to selected the proper (region of) CpG island upstream of each of the 
five genes/loci CDKN2A(p16), MLH1, MINT1, MINT2 and MINT31; as these articles 
represent pilot reports and the basis for many other studies characterizing the same 
genes/gene panel, regarding the selection of CpG island and primer sequences. 
Therefore, in addition to the new primers designed in this work, the same primer 
sequences used in those articles were purchased. Since these primers mentioned before 
were used in MSP techniques, they were considered as a possible alternative if the newly 
designed primers could not be used. In fact, this was the case of CDKN2A(p16), for 
which previously mentioned primer sequences were used instead. Moreover, both newly 
design and Issa’s primer sequences for MINT31 failed to amplify correctly, and therefore, 
new primer sequences were selected for this locus, based on the work by Weisenberger 
et al (2006)125. The final primer sequences employed to test all samples by qMSP, and 
their associated characteristics are summarized in Table 3. 
Quantitative methylation-specific polymerase chain reaction (qMSP) 
Quantitative real-time methylation specific PCR was performed using 
NZYSpeedy qPCR Green Master Mix with ROX (2X) (NZYTech, Lda., Lisbon, Portugal), 
and β‑actin (ACTB) as the reference gene, to analyse CpG islands methylation levels of 
CDKN2A(p16), MLH1 and MINT1, 2 and 31 promoters, in all tissue samples. Reactions 
were carried out in 384-well plates using a LightCycler 480 instrument II (Roche, 
Mannheim, Germany). Briefly, per each well 2 μL of modified DNA, 5 μL of Master Mix 
and 0.3 μL of working primers’ solution 10 μM were added. Double-distilled water was 
also added to complete the final volume (10 μL). To prepare working primers’ solutions, 
10 μL of each front (F) and respective reverse (R) primer’s solution (100 μM) were diluted 
in 180 μL of double-distilled water. The PCR program comprised a period of 3 minutes 
at 95°C to activate the enzyme, followed by 45 cycles with 3 seconds at 95°C (for DNA 
denaturation) and 30 seconds at a specific annealing temperature for each gene (for 
annealing, extension and data acquisition) [see Table 3 for annealing temperature data]. 
An additional dissociation stage was included. All samples were run in triplicates and in 
each plate five negative template controls were also run. Universal Methylated Human 
DNA Standard (Zymo Research Corp., Irvine, CA, USA) was used to generate five serial 
dilutions by a 5X dilution factor. These serial dilutions were run in each plate and were 
used to generate a standard curve, thus allowing for absolute quantification and 
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determination of PCR efficiency. A run was considered valid when the slope of each 
standard curve was above -3.60, corresponding to PCR efficiencies of > 90%, and R2 
value of at least 5 relevant data points exceeded 0.96. The relative level of methylated 
DNA for each gene/locus in each sample was determined using the formula: [(target 
gene/(β-actin) x 1000]. Analysis of the qMSP data was performed using LightCycler® 
480 software 1.5.0 SP3 (Roche, Mannheim, Germany).  
To confirm the amplification of the specific product in standards and samples, the 
melting curve and melting temperature data were analysed and only those samples 
amplifying the specific product for each gene/locus were selected. For each of the 
selected tumour samples, a specific gene/locus was proposed to be methylated if the 
value of the previously described ratio was superior to any of the ratio values for the 
selected control samples, considering the same gene/locus. When none of the control 
samples amplified the specific product, all the selected tumour samples were proposed 
to be methylated. However, only those samples with a ratio value greater than the 
correspondent 25th percentile were considered to be methylated. 
Statistical analysis 
 Statistical analyses were performed using the statistical program SPSS software 
(IBM SPSS® Statistics version 24.0, Chicago, IL, USA). All P-values were two-sided, 
and statistical significance was set at P <0.05. Methylation of MLH1 was excluded from 
all statistical analysis due to the small number of methylated cases. Categorical 
clinicopathological and molecular variables were compared to CIMP status and 
methylation of each marker using the Chi-square test or the Fisher’s exact test, as 
applicable. Age was considered a categorical variable, and was further divided in two 
groups according to median age, which was highly similar to mean age value. In addition, 
the Chi-square analysis for N stage in MINT1 methylated tumours was replaced by 
Fisher’s exact test because of the small number of methylated cases. For that purpose, 
N3 and N4 stage groups were merged. Likewise, AJCC stage and specifically T stage 
variables were clustered in two groups (lower and higher stages) to avoid small groups 
to be analysed. Nonetheless, the analysis of some variables originated groups with less 
than 5 elements, when analysing either the panel or the methylation of each marker. 
Moreover, the clinicopathological factor tumour grade (G) was excluded from this initial 
analysis, since almost all of the tumours were G2 (moderately differentiated), precluding 
a correct statistical analysis for most of the studied groups. 
Disease-specific survival time was measured from the date of diagnosis to the 
date of death due to the progression of the disease, or the last clinical follow-up time for 
surviving patients (censored). No patient from this cohort has died from other causes 
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apart from CRC. Disease-free survival time was measured from the date of surgery or 
the last treatment performed (considering the patient was cured) to the date of 
recurrence or the last clinical follow-up time (censored). In the case of multiple 
recurrences, only the time elapsed by the first event was considered. Disease-specific 
survival (DSS) and DFS were evaluated using log-rank statistic P-values for differences 
in survival based on Kaplan-Meier’s approach (including graphical representations). Cox 
proportional hazard regression model was used to calculate hazard ratios (HRs) of death 
or recurrence according to clinical and molecular (KRAS, CIMP, methylation of markers) 
features; and multivariable analysis was used to determine independent prognostic 
factors. Due to the lack of enough representative cases, tumour grade was excluded 
from the DFS analysis, and T3 and T4 tumours were joint in the same group. Likewise, 
T1 and T2, as well as stage I and stage II or G1 and G2 tumours were combined in the 
same group for all statistical tests. Moreover, throughout the descriptive text, P-values 
mentioned correspond to Cox proportional hazard regression model. 
 
Table 3 - List of primers’ sequences used and respective chromosomal location, size of the generated amplicon, 
temperature of annealing, GenBank Accession number and specific location in the accessed sequence. 
 
  
Gene or 
locus 
Chrom. 
location Sequence (5’–3’) 
Size, 
bp 
T 
Annealing, 
ºC 
GenBank 
Accession 
No. 
Location, bp 
ACTB-F 
ACTB-R 7p22.1 
TGGTGATGGAGGAGGTTTAGTAAGT 
AACCAATAAAACCTACTCCTCCCTTAA 133 60 Y00474 390–522 
CDKN2A-F 
CDKN2A-R 9p21 
TTATTAGAGGGTGGGGCGGATCGC 
GACCCCGAACCGCGACCGTAA 150 65 AF527803 19906–20056 
MINT1-F 
MINT1-R 5q13-14 
GGAGAGTAGGGGAGTTCGC 
CTTCGCCTAACCTAACGC 119 62 AF135501 212-331 
MINT2-F 
MINT2-R 2p22-21 
TTTAGTATTTAAGTTCGTTGGC 
ACGATTCCGTACGCCTTT 117 60 AF135502 431–548 
MINT31-F 
MINT31-R 17q22 
GTCGTCGGCGTTATTTTAGAAAGTT 
CACCGACGCCCAACACA 72 60 AC021491 50059-50131 
MLH1-F 
MLH1-R 3p21.3 
GTAGTCGTTTTAGGGAGGGAC 
TCAATACCTCGTACTCACGTTC 156 64 AY217549 1750-1906 
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RESULTS 
PROJECT I 
Considering tumour samples, the group of selected patients included nine men 
and one woman, with a median age of 64 years old (range 53-67). Two patients were 
diagnosed with AJCC stage I, two as stage II, three as stage III, and three as stage IV. 
All patients had adenocarcinomas; in eight patients the tumour was localized in the colon, 
while two patients had rectal cancer. In nine patients the tumour was of moderately 
differentiated grade (G2), but poorly differentiated (G3) in the other patient. One patient 
with colon cancer received neoadjuvant therapy (RT) before surgery. 
 When no correction to multiple t-tests was applied, a few significant changes of 
expression were spotted [Tables 4 and 5]. However, the profiling analysis of 90 lncRNAs 
revealed that no transcript was differentially expressed between any pair of the four 
groups compared, after Holm-Šídák correction. Likewise, no difference was found 
comparing all tumour samples with healthy mucosa equivalents, or pitting all samples 
with lower BER repair capacity against samples presenting higher BER repair capacity 
[Table 6]. Nevertheless, those previous results, depicted in Table 4 and 5, will be 
described herein, albeit bearing in mind the loss of significance after employing the 
correction model. 
After comparing each pair of the four groups, fifteen different transcripts were 
found to be up or down-regulated. SNHG4, LUST, GAS5-family of transcripts, E2F4 
antisense, anti-NOS2A and BACE1AS family of transcripts were all found to be down-
regulated in lower BER repair capacity tumours compared to healthy mucosa samples 
with the opposite behaviour. GAS5 (family) and E2F4 antisense transcripts were also 
found to be down-regulated in TH group compared to HH group, while MEG9 was found 
to be up-regulated. Except from mascRNA, all down-regulated transcripts in TL group 
were commonly affected in TH group, when each of these two groups was compared to 
HL group. Likewise, IGF2AS family of transcripts expression was found to be altered in 
both groups of tumours compared with HL group, but in this case the transcript was up-
regulated. Furthermore, the biggest fold change was reported for IGF2AS transcripts. 
The analysis of repair capacity within tumour or healthy mucosa groups of samples 
revealed seven transcripts down-regulated in healthy mucosa with the increase of the 
repair capacity, but no differences were found comparing TH and TL groups [Table 4]. 
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Table 4 - Long noncoding RNAs differentially expressed between the four groups of samples formed HH, HL, TH 
and TL, before Holm-Šídák correction. Significant P-values (P<0.05) not adjusted are represented below the Fold 
Change values. No lncRNA was found to be differently expressed between TL and TH groups. After adjustment of P-
value according to Holm-Šídák correction for multiple comparisons, no significant differences were found. HH: Healthy 
mucosa with Higher levels of BER repair capacity, HL:  Healthy mucosa with Lower levels of BER repair capacity, TH:  
Tumour with Higher levels of BER repair capacity, TL: Tumour with Lower levels of BER repair capacity. 
LncRNAs HH HL HL 
 TH TL TL TH HH 
H19 antisense   -3.10 (0.043) 
-3.50 
(0.023)  
Zfas1   -7.01 (0.020) 
-12.27 
(0.013) 
-7.61 
(0.017) 
SNHG4  -2.58 (0.018)    
SAF   -4.83 (0.045) 
-11.38 
(0.020) 
-7.07 
(0.028) 
HOTAIRM1   -7.07 (0.024) 
-9.34 
(0.020) 
-8.43 
(0.021) 
IGF2AS (family)   41.22 (0.003) 
17.90 
(0.025)  
RNCR3   -14.32 (0.033) 
-24.79 
(0.029) 
-12.98 
(0.035) 
LUST  -7.17 (0.003)    
GAS5-family -4.03 (0.015) 
-2.68 
(0.005)    
E2F4 antisense -5.49 (0.010) 
-1.52 
(0.005)    
anti-NOS2A  -2.07 (0.024)    
BACE1AS (family)  -1.83 (0.049)    
Jpx   -14.42 (0.021) 
-7.04 
(0.032) 
-11.40 
(0.023) 
mascRNA   -5.69 (0.043)  
-4.81 
(0.048) 
MEG9 2.58 (0.017)    
-12.05 
(0.047) 
 
Additionally, Zfas1, H19 antisense and SNHG4 persisted as down-regulated 
transcripts after comparing all tumours with all healthy mucosa samples, irrespective of 
repair capacity. In the same manner, Zfas1, SAF and HOTAIRM1 were not only down-
regulated comparing HH to HL groups, but also when all samples with higher BER repair 
capacity (both tumours and healthy mucosa) were compared with all samples with lower 
repair capacity. Moreover, two additional transcripts (ST7OT and lincRNA-p21) were 
also found to be down-regulated in tumour samples [Table 5]. 
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Table 5 - Long noncoding RNAs differentially expressed between Healthy mucosa and Tumour samples, and 
samples with Lower and High BER repair capacity, before Holm-Šídák correction. Significant P-values (P<0.05) not 
adjusted are represented after the Fold Change values. After adjustment of P-value according to Holm-Šídák correction 
for multiple comparisons, no significant differences were found. 
LncRNAs Healthy vs. Tumour Lower vs. Higher 
H19 antisense -2.72 (0.015)  
Zfas1 -5.05 (0.038) -5.37 (0.033) 
SNHG4 -5.63 (0.044)  
SAF  -5.26 (0.031) 
HOTAIRM1  -5.06 (0.038) 
ST7OT -7.89 (0.018)  
lincRNA-p21 -2.67 (0.026)  
 
Table 6 - P-values for the differential expression of long noncoding RNAs between the four groups of samples 
formed HH, HL, TH and TL, and between Healthy mucosa and Tumour samples or samples with Lower and High 
BER repair capacity, after Holm-Šídák correction. After adjustment of P-value for the results  described previously, no 
significant differences were found.  
LncRNAs HH HL HL Healthy 
vs. 
Tumour 
Lower 
vs. 
Higher  TH TL TL TH HH 
H19 antisense   0.976 0.868  0.749  
Zfas1   0.835 0.701 0.793 0.966 0.949 
SNHG4  0.788    0.979  
SAF   0.978 0.833 0.916  0.940 
HOTAIRM1   0.876 0.833 0.849  0.968 
IGF2AS (family)   0.269 0.886    
RNCR3   0.943 0.916 0.952   
LUST  0.250      
GAS5-family 0.748 0.348      
E2F4 antisense 0.599 0.381      
anti-NOS2A  0.875      
BACE1AS (family)  0.987      
Jpx   0.849 0.935 0.877   
mascRNA   0.976  0.984   
MEG9 0.789    0.984   
ST7OT      0.801  
lincRNA-p21      0.905  
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PROJECT II 
Patients’ characteristics and CpG island methylation at specific loci 
Of the 211 CRC cases, 34.1% (n=72) were females and 65.9% (n=139) were 
males, with a median age at diagnosis of 61 years (61.5 years for women and 60.0 years 
for men). Almost half of all cases (49.3%) were identified in the rectum (n=104), while 
34.1% were found in the distal colon (n=72) and 16.6% in the proximal colon (n=35). 
Moreover, 39.3% of all tumours were KRAS mutated (n=83). Regarding stage, one CRC 
case was T1, 21 cases were T2, 170 were T3 stage and 16 were T4 staged. Therefore, 
88.2% of all cases were in a locally advanced stage (T3&T4). Most of the cases displayed 
lymph node metastasis, 30.4% at a N1 stage (n=64) and 31.3% at a N2 stage (n=66); 
and 50.7% (n=107) displayed distant metastasis at the time of diagnosis. Accordingly, 
most patients were also diagnosed with advanced AJCC stages of the disease. In fact, 
more than half of all patients (n=107) were diagnosed with stage IV, 24.6% with stage III 
and the remaining 23.7% with stages I or II. In addition, a fraction of all patients (32.7%) 
was submitted to neoadjuvant therapy, whereas the majority of the studied patients 
received adjuvant therapy at some point during the follow-up (80.1%). The main 
clinicopathological and molecular variables of the 211 selected CRC cases are depicted 
in Table 7. 
CIMP status was evaluated by the quantitative method SYBR® Green-based 
qMSP of a five genes/loci panel previously reported. MINT31 showed the highest 
methylation frequency, whereas MLH1 displayed the lowest, with 15.2% and 0.9%, 
respectively. Methylation frequencies of the remaining genes were 6.6% for MINT1, 
14.7% for MINT2 and 11.4% for CDKN2A(p16). Significant positive associations were 
found among MINT1, MINT2, MINT31, and CDKN2A(p16) methylation levels, suggestive 
of a hypermethylator phenotype (CIMP) in a subset of cases [Fig.5]. Since MLH1 was 
found to be methylated only in two cases, no statistical analysis was performed. When 
methylation of all genes/loci was grouped based on methylation of 0 or 1 marker versus 
>1 marker for the CIMP phenotype, 18 patients were defined as CIMP positive (8.5%) 
and 193 patients were defined as CIMP negative (91.5%). In a trichotomous 
categorization model, 136 patients were classified as CIMP-0, 72 patients as CIMP-L 
and three patients as CIMP-H (two patients with 4 methylated markers and one patient 
with all 5 markers methylated). Regarding CIMP-L patients, 57 only presented one 
methylated gene, while 12 were methylated in 2, and 3 patients displayed methylation in 
3 genes [Fig.5].  
Two of all patients had no information regarding tumour invasion depth (T), lymph 
node metastasis (N) and distant metastasis (M). Therefore, those patients had no AJCC 
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stage information. Additionally, four other patients had no N stage information, and for 
14 of all patients KRAS mutation status was not determined. In 211 patients with 
clinicopathological and molecular characteristics available for analyses, no statistically 
significant differences were found between CIMP+ and CIMP– tumours. However, CIMP-
L cases were more likely to present ≥4 regional lymph nodes metastasis (P=0.018), and 
strongly associated with mutated KRAS (P<0.001) [Fig.6][Table 7]. Similarly to CIMP+/– 
status, individual methylation status of MINT2 and CDKN2A(p16) did not associate with 
any of the studied variables. However, MINT31 methylation associated with mutated 
KRAS (P=0.004) [Fig.6], while MINT1 methylation associated with the absence of 
regional lymph nodes metastasis (P=0.017) [Table 8] [Appendix I].  
Due to the small number of CIMP-H cases, this category was excluded from the 
statistical analysis. However, worth of mention, two of the CIMP-H tumours were 
biopsied from female patients and were IIA (T3N0M0) staged, while the male patient was 
diagnosed with a IVA (T3N0M1a) stage tumour. All three patients were older than 61. 
Moreover, none of the three tumours were located in the rectum – two tumours were 
found in the distal colon and one in the proximal colon –, and only one tumour presented 
mutated KRAS (data not shown). 
The same statistical analysis performed excluding all patients receiving 
neoadjuvant therapy revealed no major differences. Indeed, CIMP-L continued to be 
significantly associated with mutated KRAS (P=0.009) and N2 stage (P=0.002). 
Likewise, MINT31 methylated cases presented a strong tendency towards KRAS 
mutated (P=0.054). However, neither MINT1 nor MINT2 methylation displayed a 
significant association with N1&2 stage after Fisher’s exact test was performed, 
considering only those 141 patients who did not receive any neoadjuvant treatment 
[Appendix II and III]. Of mention, no information concerning neoadjuvant therapy was 
available for one of the 211 patients. 
The analysis of KRAS mutations revealed that almost all of these were located in 
the second exon of the gene – one was located in exon 3 and another sample presented 
a mutation in exon 4 of the KRAS gene. Furthermore, one mutated KRAS sample had 
no further information regarding the specific exon altered. Considering only mutations in 
the second exon of the gene, nine different single mutations affecting mostly Glycine 12 
or Glycine 13 were found. However, none of the described substitutions of Glycine by 
another residue were correlated with any of the two CIMP categorizations or methylation 
of any marker, particularly CIMP-L and methylation of MINT31 (data not shown). 
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Fig.5 - Performance of the classic CIMP panel. The 211 tumours were screened against the classic set of CIMP 
markers. The alignment of each tumour is maintained across all analysis. At the left side: dichotomous heat maps 
representing DNA methylation data for all 5 genes/loci (red: methylayed, light blue: unmethylated), and resultant CIMP 
categorization according to both dichotomous (black: CIMP+, light grey: CIMP–) and trichotomous (red: CIMP-H, black: 
CIMP-L, light grey: CIMP-0) models. At the right side: histogram of the methylation frequency distribution for the set of 
classic CIMP markers. 
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Table 7 - Distribution of clinicopathological and molecular variables for all CRC patients and association with 
CIMP status. Number of cases (and respective percentage) distributed per each category from all CRC cases (N=211), 
excluding tumour grade. Dichotomous (positive/negative) and trichotomous (CIMP-0, CIMP-Low and excluding CIMP-
High) CIMP categorization, and its distribution and association with all represented variables. P-values were calculated 
using the Chi-squared test or the Fisher’s exact test. Significant P-values (P<0.05) are represented in bold. 
*P-Value calculated with >20% cells having expected counts less than 5. 
Variables Cases (%) CIMP- CIMP+ CIMP-0 CIMP-L 
  No. % No. % No. % No. % 
  193 91.5 18 8.5 136 64.5 72 34.1 
Gender 
Female 
Male 
 
72 (34.1) 
139 (65.9) 
 
64 
129 
 
33.2 
66.8 
 
8 
10 
 
44.4 
55.6 
 
44 
92 
 
32.4 
67.6 
 
26 
46 
 
36.1 
63.9 
 P=0.437 P=0.644 
Age at diagnosis 
≤61 (median age) 
>61 
 
114 (54.0) 
97 (46.0) 
 
108 
85 
 
56.0 
44.0 
 
6 
12 
 
33.3 
66.7 
 
75 
61 
 
55.1 
44.9 
 
39 
33 
 
54.2 
45.8 
 P=0.084 P=1.000 
Tumour location 
Rectum 
Distal Colon 
Proximal Colon 
 
104 (49.3) 
72 (34.1) 
35 (16.6) 
 
92 
68 
33 
 
47.7 
35.2 
17.1 
 
12 
4 
2 
 
66.7 
22.2 
11.1 
 
66 
51 
19 
 
48.5 
37.5 
14.0 
 
38 
29 
15 
 
52.8 
26.4 
20.8 
 P=0.304* P=0.197 
KRAS status 
Wild-type 
Mutated 
ND 
 
114 (54.1) 
83 (39.3) 
14 (6.6) 
 
108 
72 
13 
 
64.7 
35.3 
- 
 
6 
11 
1 
 
40.0 
60.0 
- 
 
87 
42 
7 
 
67.4 
32.6 
- 
 
25 
40 
7 
 
38.5 
61.5 
- 
 P=0.070 P<0.001 
AJCC stage 
I&II 
III&IV 
ND 
 
50 (23.7) 
159 (75.4) 
2 (0.9) 
 
45 
146 
2 
 
23.6 
76.4 
- 
 
5 
13 
- 
 
27.8 
72.2 
- 
 
30 
105 
1 
 
22.2 
77.8 
- 
 
18 
53 
1 
 
25.4 
74.6 
- 
 P=0.773 P=1.000 
Tumour invasion depth (T) 
T1&T2 
T3&T4 
ND 
 
22 (10.4) 
186 (88.2) 
3 (1.4) 
 
19 
172 
3 
 
9.90 
90.1 
- 
 
3 
15 
- 
 
16.7 
83.3 
- 
 
15 
120 
2 
 
11.1 
88.9 
- 
 
7 
64 
1 
 
9.90 
90.1 
- 
 P=0.413 P=1.000 
Lymph node metastasis (N) 
N0 
N1 
N2 
ND 
 
75 (35.5) 
64 (30.4) 
66 (31.3) 
6 (2.8) 
 
67 
62 
58 
6 
 
35.8 
33.2 
31.0 
- 
 
8 
2 
8 
- 
 
44.4 
11.2 
44.4 
- 
 
48 
49 
35 
4 
 
36.4 
37.1 
26.5 
- 
 
24 
15 
31 
2 
 
34.3 
21.4 
44.3 
- 
 P=0.149 P=0.018 
Distant Metastasis (M) 
M0 
M1 
ND 
 
102 (48.4) 
107 (50.7) 
2 (0.9) 
 
94 
97 
2 
 
49.2 
50.8 
- 
 
8 
10 
- 
 
44.4 
55.6 
- 
 
65 
70 
1 
 
48.1 
51.9 
- 
 
35 
36 
1 
 
49.3 
50.7 
- 
 P=0.807 P=0.885 
Neoadjuvant therapy 
Yes 
No 
ND 
 
69 (32.7) 
141 (66.8) 
1 (0.5) 
 
62 
130 
1 
 
32.3 
67.7 
- 
 
7 
11 
- 
 
38.9 
61.1 
- 
 
43 
92 
1 
 
31.9 
68.1 
- 
 
26 
46 
- 
 
36.1 
63.9 
- 
 P=0.604 P=0.540 
Adjuvant therapy 
Yes 
No 
 
169 (80.1) 
42 (19.9) 
 
154 
39 
 
79.8 
20.2 
 
15 
3 
 
83.3 
16.7 
 
108 
28 
 
70.4 
20.6 
 
59 
13 
 
81.9 
18.1 
 P=1.000 P=0.717 
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Table 8 - Association between clinicopathological and molecular variables and each of the five genes/loci 
constituting the classic CIMP panel. Classification of tumours according to the methylation status of each gene or locus 
(MINT1, MINT2, MINT31 and CDKN2A(p16)), and its distribution and association with all represented variables. P-values 
were calculated using the Chi-squared test or the Fisher’s exact test. Significant P-values (P<0.05) are represented in 
bold. To avoid oversizing of the table, non-significant results for tumour invasion depth (T), distant metastasis (M), 
neoadjuvant and adjuvant therapies variables were excluded from the represented table. A complete version of this table 
is depicted in Appendix I. 
Variables MINT1 MINT2 MINT31 CDKN2A(p16) 
 M UM M UM M UM M UM 
 No. % No. % No. % No. % No. % No. % No. % No. % 
 14 6.6 197 93.4 31 14.7 180 89.6 32 15.2 179 84.8 24 11.4 187 88.6 
Gender 
Female 
Male 
 
8 
6 
 
57.1 
42.9 
 
64 
133 
 
32.5 
67.5 
 
11 
20 
 
35.5 
64.5 
 
61 
119 
 
33.9 
66.1 
 
14 
18 
 
43.8 
56.3 
 
58 
121 
 
32.4 
67.6 
 
7 
17 
 
29.2 
70.8 
 
65 
122 
 
34.8 
65.2 
 P=0.080 P=0.841 P=0.229 P=0.654 
Age 
≤61 
>61 
 
6 
8 
 
57.1 
42.9 
 
108 
89 
 
54.8 
45.2 
 
12 
19 
 
38.7 
61.3 
 
102 
78 
 
56.7 
43.3 
 
16 
16 
 
50.0 
50.0 
 
98 
81 
 
54.7 
45.3 
 
11 
13 
 
45.8 
54.2 
 
103 
84 
 
55.1 
44.9 
 P=0.418 P=0.079 P=0.701 P=0.515 
Location 
Rectum 
Distal  
Proximal  
 
6 
5 
3 
 
42.9 
35.7 
21.4 
 
98 
67 
32 
 
49.7 
34.0 
16.3 
 
18 
8 
5 
 
58.1 
25.8 
16.1 
 
86 
64 
30 
 
47.8 
35.6 
16.7 
 
14 
9 
9 
 
43.8 
28.1 
28.1 
 
90 
63 
26 
 
50.3 
35.2 
14.5 
 
14 
6 
4 
 
58.3 
25.0 
16.7 
 
90 
66 
31 
 
48.1 
35.3 
16.6 
 P=0.840* P=0.520 P=0.160 P=0.574 
KRAS  
WT 
Mutated 
ND 
 
5 
8 
1 
 
38.5 
61.5 
- 
 
109 
75 
13 
 
59.2 
40.8 
- 
 
12 
17 
2 
 
41.4 
58.6 
- 
 
102 
66 
12 
 
60.7 
39.3 
- 
 
10 
20 
2 
 
33.3 
66.7 
- 
 
104 
63 
12 
 
62.3 
37.7 
- 
 
9 
12 
3 
 
42.9 
57.1 
- 
 
105 
71 
11 
 
59.7 
40.3 
- 
 P=0.158 P=0.067 P=0.004 P=0.164 
AJCC stage 
I&II 
III&IV 
ND 
 
5 
8 
1 
 
38.5 
61.5 
- 
 
45 
151 
1 
 
23.0 
77.0 
- 
 
9 
22 
- 
 
29.0 
71.0 
- 
 
41 
137 
2 
 
22.6 
77.4 
- 
 
10 
22 
- 
 
31.3 
68.7 
- 
 
40 
137 
2 
 
22.6 
77.4 
- 
 
5 
19 
- 
 
24.9 
75.1 
- 
 
45 
140 
2 
 
24.3 
75.7 
- 
 P=0.310 P=0.496 P=0.367 P=0.804 
N 
N0 
N1/(N1&2) 
N2 
ND 
 
9 
4 
- 
1 
 
69.2 
30.8 
- 
- 
 
66 
126 
- 
5 
 
34.4 
65.6 
- 
- 
 
11 
5 
14 
1 
 
36.6 
16.7 
46.7 
- 
 
64 
59 
52 
5 
 
36.6 
33.7 
29.7 
- 
 
14 
6 
12 
- 
 
43.3 
18.8 
37.5 
- 
 
61 
58 
54 
6 
 
35.3 
33.5 
31.2 
- 
 
8 
5 
11 
- 
 
25.0 
29.2 
45.8 
- 
 
67 
59 
55 
6 
 
37.0 
32.6 
30.4 
- 
 P=0.017 P=0.097 P=0.253 P=0.275 
*P-Value calculated with >20% cells having expected counts less than 5. 
M, methylated; UM, unmethylated; WT, wild-type.  
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Fig.6 - Comparison between the classic CIMP panel, MINT31 methylation and KRAS mutation status. The 211 
tumours were screened against the classic set of CIMP markers. The alignment of each tumour is maintained across all 
analysis. At the left side: simplified heat maps representing trichotomous CIMP categorization (red: CIMP-H, black: CIMP-
L, light grey: CIMP-0), MINT31 methylation (red: methylayed, light blue: unmethylated), and KRAS mutation status (green: 
wild-type, blue: mutated, white: not determined). Right side: relative frequencies of KRAS mutation for CIMP-0 and CIMP-
L tumours, with colour codings as described above. WT, wild-type; M, mutated; ND, not determined. 
Prognostic factors for survival: disease-specific survival 
The DSS for one of the 211 CRC patients could not be determined. The median 
follow-up of all 210 CRC patients was 52 months (range: 5–212 months). At the time of 
the last follow-up, 14 patients were alive with no evidence of cancer, 11 patients were 
alive with cancer progression, while the remaining 185 patients had deceased (due to 
CRC progression). The DSS rate of the 210 patients was 99.5%, 40.7% and 5.5% at 
one, five and ten years of follow-up, respectively. Univariable survival analysis showed 
a significant association between a decrease in DSS and an older age at diagnosis 
(P=0.005) [Fig.7A], locally advanced tumour stage (T4) (P<0.001), ≥4 regional lymph 
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node metastasis (N2) (P=0.024) and distant metastasis (P<0.001), as well as with AJCC 
tumour stage IV (P<0.001) [Fig.7B] and neoadjuvant therapy (P=0.040) [Fig.7C]. The 
remaining clinicopathological and molecular parameters presented no prognostic value 
as they were not significantly associated with DSS. However, a trend towards decreased 
DSS was reported for less differentiated tumours (G3) (P=0.066). Importantly, the total 
number of G3 tumours was critically small and thus, this result shall be interpreted 
cautiously [Table 9]. 
In a multivariable analysis, using Cox proportional hazard regression model, older 
age at diagnosis, higher AJCC tumour stage (IV) and neoadjuvant therapy were 
independently associated with decreased DSS (P=0.034, P<0.001 and P=0.040, 
respectively) [Table 9]. Indeed, the risk of death due to the progression of the disease 
for older patients and patients submitted to neoadjuvant therapy was, respectively, 1.387 
(95% CI 1.024-1.877) and 1.406 (95% CI 1.032-1.914) times higher, while patients 
diagnosed with stage IV tumours had an increased risk of 1.887 (95% CI 1.309-2.719, 
P=0.001) and 1.912 (95% CI 1-332-2.745, P<0.001) times relative to stages I&II and 
stage III tumours, respectively. T, N and M individual stages were intentionally excluded 
from the multivariable analysis as each of these are inherent to the AJCC staging, by 
definition, and may be considered linearly dependent by the software of analysis 
(particularly M stage). 
According to the general analysis, including all 210 CRC cases, neither CIMP+/- 
(1.192 95% CI 0.732-1.941, P=0.481) nor CIMP-0/L (0.952 95% CI 0.700-1.294, 
P=0.753) categorization of tumours displayed significant differences in DSS [Table 9] 
[Fig.7E,F]. Likewise, after exclusion of all 68 patients treated with neoadjuvant therapy, 
no significant association with CIMP panel was found [Appendix IV].  
Considering only CIMP+ cases, metastatic tumours were significantly associated 
with worse outcome (P=0.003), and tumours at stages III&IV presented a slight trend 
towards worse prognosis (P=0.080) [Appendix V]. Once more, this result shall be 
interpreted cautiously due to the small number of CIMP+ cases. In CIMP– group, the 
variables independently associated with worse prognosis were the same as in the 
general analysis, as this group contains almost all cases (not shown). In CIMP-0 
tumours, proximal colon localization (P=0.001) and AJCC tumour stage IV (P=0.008) 
were independently associated with a decrease in DSS; while in CIMP-L tumours, 
neoadjuvant therapy (P=0.018) and mutated KRAS (P=0.002) were independently 
associated with worse and better outcome, respectively [Appendix V]. Although no 
statistical analysis was performed for CIMP-H, all three patients eventually deceased 
from disease progression, with DSS times of circa 86, 55 and 27 months, respectively 
(data not shown). 
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Methylation of MINT loci and CDKN2A(p16) were closely interrelated, and it was 
considered possible that the adverse effects of methylation of one member of the group 
could be incorrectly ascribed to tumours displaying a generalized methylator phenotype. 
Therefore, the prognostic significance of each of the four markers was independently 
examined. Methylation of each MINT loci did not associate with disease outcome. Only 
CDKN2A(p16) methylation associated with worse outcome in a univariable analysis 
(1.578 95% CI 1.016-2.450, P=0.042) [Table 9] [Fig.8D]. However, the significance was 
lost in a multivariable analysis, although borderline (HR 1.561 95% CI 0.999-2.440, 
P=0.051) [Table 9]. After exclusion of all 68 patients subjected to neoadjuvant therapy, 
CDKN2A(p16) methylation was independently associated with worse prognosis (HR 
1.838, 95% CI, 1.090-3.097, P=0.022) [Appendix IV]. 
 
Table 9 - Univariable and multivariable prognostic analyses: disease-specific survival analysis of CRC patients 
according to represented variables and CIMP panel/markers methylation. One patient had no information regarding 
the estimation of DSS. Multivariable analysis was performed considering only those variables presenting a P-value<0.05 
in the univariable analysis (excluding T, N and M stages). Significant P-values (P<0.05) are represented in bold. 
Variables Univariable analysis Multivariable analysis 
 Median (mo) (95 % CI) P
a HR (95 % CI) Pb HR (95 % CI) Pb 
Gender 
Female (72) 
Male (138) 
 
55.5 (43.8-56.8) 
50.3 (48.1-62.9) 
0.998  
1 (referent) 
1.000 (0.735-1.359) 
 
- 
0.998 
  
Age 
≤61 (113) 
>61 (97) 
 
57.1 (49.6-64.7) 
48.8 (42.1-55.5) 
0.005  
1 (referent) 
1.520 (1.132-2.042) 
 
- 
0.005 
 
1 (referent) 
1.387 (1.024-1.877) 
 
- 
0.034 
Location 
Rectum (103) 
Distal (72) 
Proximal (35) 
 
55.5 (45.3-65.7) 
55.8 (48.8-62.8) 
44.7 (29.6-59.7) 
0.223  
0.715 (0.476-1.072) 
0.710 (0.460-1.096) 
1 (referent) 
0.226 
0.104 
0.122 
- 
  
KRAS 
WT (113) 
Mutated (83) 
 
51.6 (45.7-57.5) 
54.2 (46.4-62.0) 
0.684  
1 (referent) 
0.938 (0.690-1.275) 
 
- 
0.684 
  
AJCC stage 
I & II (50) 
III (51) 
IV (107) 
 
59.6 (56.8-62.4) 
66.4 (57.3-75.5) 
41.6 (36.9-46.3) 
<0.001  
0.530 (0.368-0.764) 
0.523 (0.364-0.751) 
1 (referent) 
<0.001 
0.001 
<0.001 
- 
 
0.534 (0.379-0.771) 
0.523 (0.364-0.753) 
1 (referent) 
<0.001 
0.001 
<0.001 
- 
T 
T1&T2 (22) 
T3 (170) 
T4 (16) 
 
63.7 (57.1-70.4) 
53.7 (48.7-58.7) 
30.7 (29.2-32.2) 
<0.001  
0.300 (0.155-0.583) 
0.307 (0.186-0.539) 
1 (referent) 
<0.001 
<0.001 
<0.001 
- 
  
N 
N0 (75) 
N1 (63) 
N2 (66) 
 
58.4 (52.9-64.0) 
59.1 (42.9-75.3) 
43.6 (33.3-53.9) 
0.023  
0.649 (0.458-0.922) 
0.649 (0.447-0.941) 
1 (referent) 
0.024 
0.016 
0.023 
- 
  
M 
M0 (101) 
M1 (107) 
 
63.3 (59.4-67.2) 
41.6 (36.9-46.3) 
<0.001  
1 (referent) 
1.899 (1.413-2.554) 
 
- 
<0.001 
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Grade 
G1&2 (125) 
G3 (5) 
 
57.1 (50.6-63.7) 
43.4 (19.8-66.9) 
0.058  
1 (referent) 
2.342 (0.944-5.807) 
 
- 
0.066 
 	
Neoadjuvant 
Yes (68) 
No (141) 
 
47.6 (40.3-54.9) 
55.8 (50.0-61.7) 
0.040  
1.377 (1.014-1.870) 
1 (referent) 
 
0.040 
- 
 
1.406 (1.032-1.914) 
1 (referent) 
 
0.040 
- 
Adjuvant 
Yes (168) 
No (42) 
 
50.1 (44.5-55.8) 
59.3 (53.0-65.7) 
0.083  
1.381 (0.957-1.993) 
1 (referent) 
 
0.085 
- 
  
CIMP 
Positive (18) 
Negative(192) 
 
51.9 (47.0-56.8) 
55.3 (36.3-54.2) 
0.481  
1.192 (0.732-1.941) 
1 (referent) 
 
0.481 
- 
  
CIMP 
CIMP-0 (136) 
CIMP-L (71) 
 
51.0 (44.1-57.9) 
54.8 (46.2-63.5) 
0.753  
1 (referent) 
0.952 (0.700-1.294) 
 
- 
0.753 
  
MINT1 
M (14) 
UM (196) 
 
50.7 (36.7-64.8) 
52.3 (47.2-57.4) 
0.926  
1.027 (0.592-1.779) 
1 (referent) 
 
0.926 
- 
  
MINT2 
M (31) 
UM (179) 
 
60.4 (53.1-67.6) 
51.6 (46.6-56.7) 
0.969  
0.992 (0.662-1.486) 
1 (referent) 
 
0.969 
- 
  
MINT31 
M (32) 
UM (178) 
 
60.4 (45.0-75.7) 
50.7 (44.7-56.6) 
0.199  
0.768 (0.513-1.150) 
1 (referent) 
 
0.200 
- 
  
P16 
M (23) 
UM (187) 
 
44.7 (31.4-57.9) 
53.4 (47.7-59.7) 
0.040  
1.578 (1.016-2.450) 
1 (referent) 
 
0.042 
- 
 
1.561 (0.999-2.440) 
1 (referent) 
 
0.051 
- 
a Log-rank test 
b Cox proportional hazard regression model 
CI, confidence interval; HR, hazard ratio; M, methylated; UM, unmethylated; WT, wild-type. 
 
Deepening the prognostic analysis, some significant associations were found 
after stratifying the test for each CIMP marker. In MINT31 methylated cases, mutated 
KRAS was independently associated with better prognosis (P=0.015). Similarly, in 
CDKN2A(p16) or MINT2 methylated tumours, an independent association between 
decreased survival and AJCC stage IV tumours was also found (relative to stage I&II 
(P=0.041) or III tumours (P=0.024), respectively) [Appendix VI]. 
Stratifying the analysis by the other molecular and clinicopathological parameters 
revealed additional significant associations between CIMP panel or individual markers 
with DSS. For instance, CDKN2A(p16) methylation associated with worse outcome in 
male patients (P=0.042), or patients with 61 years old or younger (P=0.024). In proximal 
tumours CIMP-L was associated with better prognosis (P=0.013) [Appendix VII], 
whereas in KRAS wild-type tumours CIMP-L was instead associated with worse 
prognosis (P=0.010). Moreover, in tumours presenting KRAS mutation, both CIMP-L and 
MINT31 methylation were associated with better outcome (P=0.015 and P=0.029, 
respectively). In the subgroup of patients without adjuvant treatment, MINT31 
methylation was associated with better prognosis (P=0.046) [Appendix VIII]. 
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		Fig.7 - Kaplan-Meier curves analysis for disease-specific survival according to age at diagnosis, AJCC tumour 
stage, neoadjuvant therapy, CIMP panel and CDKN2A(p16) methylation status. All four variables that were found to 
be associated with worse DSS after the multivariable analysis were screened through the Kaplan-Meier survival plot. A: 
older age at diagnosis was associated with reduced DSS; B: AJCC stage IV tumours were associated with reduced DSS; 
C: neoadjuvant therapy was associated with reduced DSS; D: methylated status of CDKN2A(p16) marker was associated 
with reduced DSS. No differences in DSS time between CIMP negative and positive tumours as well as between CIMP-
0 and CIMP-Low tumours were found (E and F, respectively).  Represented P-values were calculated by the Log-rank 
test. 
A 
C 
B 
D 
E F 
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Prognostic factors for survival: disease-free survival 
Of the 211 CRC patients, only 109 patients (51.6%) were used for the DFS 
analysis. The median DFS time of the 109 CRC patients was 16 months (range: 2–111 
months). At the time of the last follow-up, 4 patients were alive with no evidence of 
recurrence, while the remaining 105 patients had at least one recurrence (9 of these 
patients had a second recurrence or more). The DFS rate for the 109 patients was 
70.6%, 18.6% and 6.6% after one year, three and five years of follow-up, respectively. 
Survival analysis showed a significant independent association between male gender 
and shorter DFS (HR 1.549, 95% CI 1.030-2.329, P=0.035) [Fig.8A]. None of the 
remaining variables significantly associated with DFS [Table 10].  
Neither the CIMP+/– panel (0.554 95% CI 0.241-1.275, P=0.161) nor individual 
CIMP markers significantly associated with DFS [Table 10] [Fig.8B,C,D]. Moreover, a 
small number of tumours presented CIMP+ or MINT1 methylation and thus, 
interpretation of the results shall be attended cautiously. Moreover, considering only 
CIMP– or CIMP-L patients, none of the parameters associated with DFS. However, in 
CIMP-0, proximal tumours were independently associated with shorter DFS (P=0.008) 
(data not shown). Considering CIMP-H cases, two of the three patients were never cured 
during the follow up time, whereas the other patient had a disease-free survival time of 
64 months (data not shown). 
 
Table 10 - Univariable prognostic analyses: disease-free survival analysis for CRC patients according to 
represented variables and CIMP panel/markers methylation. A total of 109 patients (51.6%) were considered for the 
analysis of DFS. Significant P-values (P<0.05) are represented in bold. 
Variables Univariable analysis 
 Median (mo) (95 % CI) P
a HR (95 % CI) Pb 
Gender 
Female (39) 
Male (70) 
 
20.6 (12.6-28.6) 
14.7 (12.3-17.0) 
0.034  
1 (referent) 
1.549 (1.030-2.329) 
 
- 
0.035 
Age 
≤61 (63) 
>61 (46) 
 
16.4 (13.2-19.5) 
16.8 (10.5-23.1) 
0.456  
1 (referent) 
1.160 (0.785-1.714) 
 
- 
0.457 
Location 
Rectum (58) 
Distal (31) 
Proximal (20) 
 
16.1 (10.1-22.1) 
21.1 (12.0-30.2) 
9.99 (7.40-12.6) 
0.126  
0.839 (0.493-1.427) 
0.575 (0.520-1.033) 
1 (referent) 
0.130 
0.517 
0.064 
- 
KRAS 
WT (59) 
Mutated (42) 
 
16.8 (13.6-20.1) 
14.3 (11.0-17.5) 
0.505  
1 (referent) 
1.149 (0.763-1.731) 
 
- 
0.506 
AJCC stage 
I & II (46) 
III (39) 
IV (23) 
 
17.6 (9.97-25.3) 
16.8 (13.7-20.0) 
13.2 (9.05-17.3) 
0.463  
1.033 (0.603-1.770) 
1.320 (0.756-2.303) 
1 (referent) 
0.465 
0.906 
0.329 
- 
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T 
T1&T2 (15) 
T3&T4 (93) 
 
24.4 (18.7-30.0) 
15.9 (13.1-18.8) 
0.249  
0.718 (0.407-1.265) 
1 (referent) 
 
0.251 
- 
N 
N0 (51) 
N1 (32) 
N2 (23) 
 
16.4 (9.93-22.8) 
17.2 (4.86-29.6) 
15.3 (12.0-18.5) 
0.183  
0.981 (0.619-1.555) 
1.546 (0.933-1.560) 
1 (referent) 
0.188 
0.936 
0.091 
- 
M 
M0 (85) 
M1 (23) 
 
16.9 (12.1-21.7) 
13.2 (9.05-17.3) 
0.597  
1 (referent) 
0.873 (0.529-1.443) 
 
- 
0.597 
Neoadjuvant 
Yes (31) 
No (78) 
 
14.5 (11.2-17.9) 
17.2 (13.1-21.3) 
0.481  
1.165 (0.761-1.784) 
1 (referent) 
 
0.481 
- 
Adjuvant 
Yes (68) 
No (41) 
 
16.8 (14.0-25.0) 
16.4 (11.7-21.8) 
0.812  
0.953 (0.643-1.414) 
1 (referent) 
 
0.812 
- 
CIMP 
Positive (6) 
Negative(103) 
 
30.6 (4.18-57.0) 
16.1 (13.8-18.4) 
0.159  
0.554 (0.241-1.275) 
1 (referent) 
 
0.161 
- 
CIMP 
CIMP-0 (70) 
CIMP-L (38) 
 
16.8 (12.1-21.6) 
14.3 (9.40-19.1) 
0.848  
1 (referent) 
1.041 (0.691-1.566) 
 
- 
0.848 
MINT1 
M (6) 
UM (103) 
 
16.1 (0.00-59.9) 
16.8 (14.1-19.5) 
0.076  
0.442 (0.175-1.115) 
1 (referent) 
 
0.084 
- 
MINT2 
M (13) 
UM (96) 
 
20.5 (3.92-37.0) 
16.4 (14.1-18.6) 
0.478  
0.808 (0.447-1.459) 
1 (referent) 
 
0.479 
- 
MINT31 
M (15) 
UM (94) 
 
17.2 (7.06-27.4) 
16.4 (13.9-18.8) 
0.546  
1.843 (0.484-1.468) 
1 (referent) 
 
0.546 
- 
P16 
M (13) 
UM (96) 
 
19.9 (10.8-29.0) 
16.4 (14.1-18.6) 
0.887  
1.043 (0.582-1.870) 
1 (referent) 
 
0.887 
- 
a Log-rank test 
b Cox proportional hazard regression model 
CI, confidence interval; HR, hazard ratio; M, methylated; UM, unmethylated; WT, wild-type. 
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		Fig.8 - Kaplan-Meier curves analysis for disease-free survival according to gender, CIMP panel and 
CDKN2A(p16) methylation status. Male gender was found to be associated with decreased DFS time (A), but no 
association was found analysing the methylation status of CDKN2A(p16) marker (B). No differences in DFS time between 
CIMP negative and positive tumours as well as between CIMP-0 and CIMP-Low tumours were found (C and D, 
respectively). Represented P-values were calculated by the Log-rank test. 
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DISCUSSION 
CRC is one of the most common malignancies in the world, and although 
screening for early detection of CRC has the potential to reduce both the incidence and 
mortality of the disease, still the overall survival rate has not changed dramatically, and 
a large number of individuals will develop CRC each year and eventually decease 
following disease progression.3 Development of CRC is a complex biological process, 
involving multiple genomic and epigenomic alterations.137 In fact, intensive investigation 
over the last few decades have focused on the comprehension of genomic mechanisms, 
and particularly the role of protein-coding genes in the pathogenesis of CRC.54 It is now 
time to explore new horizons that may very well represent the target for future treatment 
options or diagnostic tools; and when the subject is not directly the genome, it is 
inevitably epigenetics, in its wide and complex web of regulatory processes involving our 
genetic material. The last few years have been essential to definitely prove the 
importance of epigenetics in cancer development and treatment. Therefore, it was the 
selected matter in this work. 
PROJECT I 
Recent studies of lncRNAs have highlighted the importance of this new class of 
the non-coding part of our genome. Enormous amount, diversity of functions and great 
flexibility may be the explanation for their commonly deregulated expression, which is 
often significantly correlated with carcinogenesis.64 
CRC has long been associated with defects in DNA repair, mostly with genetic 
alterations and aberrant DNA methylation of MMR genes. In contrast, BER and NER 
pathways are not described as significantly related with CRC development and outcome 
in most genetic studies published. However, more intense research is needed to achieve 
a better understanding of these repair mechanisms in the particular case of CRC, and 
completely rule out an important role played by either BER or NER pathways in the 
development of the disease. In an effort to help tackling the problem, the first project 
presented here was dedicated to the epigenetic study of the BER repair pathway in 
sporadic CRC, through the evaluation of differential expression of lncRNAs.  
The analysis of expression levels of ninety disease-related lncRNAs revealed that 
none of the tested transcripts was differently expressed between any pair of groups 
compared. Moreover, when comparing all ten CRC samples with the other ten healthy 
mucosa samples no significant differences were also found. One explanation for such 
lack of significant results may rely on the high inter-individual expression variability of 
lncRNAs, even considering the same cell type,162 which suggests not only different 
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epigenetic patterns in different tissues, but also potential changes environmentally 
induced.163 Indeed, most of the selected samples were not paired and the population 
studied presented high variability irrespective of clinicopathological variables, including 
one patient that received neoadjuvant therapy. Notably, lncRNA annotations differ not 
just between tissues, but also between closely related cell types.163 Therefore, a different 
location of the studied cases in the large bowel, extracted either from the tumour or 
normal mucosa, and a different content of each cell type in those samples, account for 
great discrepancies in expression levels. The fact that each lncRNA is often involved in 
a wide range of cellular mechanisms with different functions61 is inevitably related with a 
higher susceptibility to expression changes upon certain conditions, such as those 
occurring during cancer progression; therefore, another major cause of variability may 
be attributed to a more or less advanced state of the tumour. In fact, the distribution of 
TNM stage among the ten tumour samples is heterogeneous, with three of them being 
classified as stage IV. Increasingly, differential expression of lncRNAs has been 
associated with tumour TNM stage, mostly higher stages.164 
An important aspect to be considered when extracting samples of normal mucosa 
from CRC patients is the possible presence of field cancerization, which may extent as 
far as 17 cm from the tumour and is initially characterized by sub-cellular alterations, 
affecting primarily labile molecular components, such as lncRNAs.165 Thus, the distance 
between the tumour and the sample extracted from an apparently normal mucosa may 
not be long enough to exclude field cancerization effect, and skewed differences in the 
expression levels of lncRNAs. 
The small number of representative samples per group coupled with the 
existence of many variability factors may have hampered the establishment of compact 
relations between any compared pair of formed groups. Although no other work following 
the same approach was published so far, many studies exist reporting differently 
expressed lncRNAs in CRC. Part of the ninety tested transcripts were formerly reported 
as being repressed or induced in CRC.72 Perhaps the most similar study was conducted 
by Thorenoor and co-workers (2015), in which tumour and paired non-tumour colorectal 
tissues of twenty CRC patients from Czech Republic were screened for the expression 
of lncRNAs using the same commercially available qPCR Array Kit. In this independent 
work six up-regulated and four down-regulated transcripts were described.166 The only 
common transcript differently altered, attending the results depicted herein without 
applying any correction to multiple t-tests, was Zfas1. However, contrarily to Thorenoor’s 
work, Zfas1 was found to be down-regulated in this present analysis. Moreover, another 
work also reported this lncRNA as being up-regulated in CRC and predicting poor 
prognosis167. Again, this contradictory observation, and the fact that the majority of the 
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transcripts were suspiciously down-regulated when no correction was applied, is likely 
the consequence of great variability and small size of the studied population, further 
reflected in the absence of significant results after applying Holm-Šídák correction. 
In the future, the analysis performed here should be repeated in a larger 
population, and reducing the variability factors to better elucidate the relation between 
BER pathway and regulation of lncRNAs in CRC. Moreover, it is important to note that 
only ninety transcripts were tested, from a universe of more than ninety thousand 
possible lncRNAs genes. High-throughput microarrays represent a more complete 
approach, while maintaining statistical power. However, to potentially detect or exclude 
any relation at all, the best initial approach would be RNA-sequencing. 
The results depicted here suggest that no association exists between BER 
pathway and CRC development, considering the expression levels of ninety lncRNAs. 
Additionally, none of the transcripts was found to be differently expressed between CRC 
tissue and normal colorectal tissue. However, previously published contradictory data, 
and high variability and small size of the studied population preclude any solid 
conclusion. 
 
PROJECT II 
Methylation represents the most well known cancer-related epigenetic alteration. 
Because DNA methylation begins early in CRC development, it is the only epigenetic 
evidence retained in purified genomic DNA isolated from tumours, and is chemically and 
biologically stable. In fact, aberrant DNA methylation is well known to play an important 
role not only in cancer onset but also during its progression, and CRC is no exception168 
In the past fifteen years, promoter CpG island DNA hypermethylation leading to 
transcriptional gene silencing has been recognized as a functional alternative to genetic 
mutations inactivating tumour suppressor genes in carcinogenesis. Furthermore, it 
should be recalled that CIMP status has been pointed out as the most promising indicator 
for prognosticating CRC patients.115 Although CIMP is now collectively accepted as a 
subtype of CRCs characterized by epigenetic instability, the same does not applies when 
selecting the best approach and group of loci used to define CIMP status of a tumour. 
Therefore, in this second project the main goal was the characterization of CIMP status 
by specific qMSP in a group of CRC patients using one of the most commonly used 
panels, the classic CIMP panel (defined by five markers).  
The analysis of typical clinicopathologic and molecular variables distribution for 
all CRC patients revealed discrepancies from previously published data. Indeed, in our 
series a higher percentage of males was enrolled, when only a slight difference favouring 
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male sex was reported in larger studied populations. Herein, patients were diagnosed at 
earlier age (one-decade difference for median age), which may be the consequence of 
a higher percentage of rectal cancers also reported, comparatively to colon tumours. 
According to the literature, patients with rectal cancer tend to be younger at diagnosis 
than those with colon cancer (median age, 63 vs 70 years, respectively). In this study, 
almost half of all patients harboured rectal tumours, in opposition to ~30% reported by 
other studies that also included consecutive series. The explanation may be in part 
related to lesions missed by colonoscopy, which are more frequently located on the right 
side of the bowel, due to poor bowel preparation that prevents complete examination. 
Moreover, symptoms are usually easier to notice when the tumour is located on the left 
side of the bowel.7,169,170 Nonetheless, the frequency of KRAS mutations are in 
accordance with the literature.27 Similarly to others, the majority of tumours were 
moderately differentiated (G2), but the frequency of G2 tumours was higher than 
previously reported, as almost all tumours were moderately differentiated.169,170 The 
percentage of tumours diagnosed with AJCC stage IV was much higher in this study 
compared to larger series.169,170 In fact, half of the cases were stage IV, which might be 
due to the lack  of a CRC screening program in our country and region.  
Concerning treatment approaches, the majority of stages II and III tumours was 
submitted to neoadjuvant therapy, including mainly rectal tumours. Moreover, half of all 
stage IV tumours were also submitted to neadjuvant treatment, most probably 
representing unresectable/difficult to resect lesions. Most patients enrolled were 
submitted to adjuvant therapy after primary treatment, because 2/3 of all tumours were 
classified as stage III or IV. Additionally, adjuvant therapy was applied after progression 
of some stage I and II cases. 
At some extend these described disparities may also arise due to different follow-
up time considered, different health policies between countries, and diverse inherent 
characteristics for different populations, even comparing western developed countries. 
However, no similar study was conducted in the Portuguese population, precluding a 
better clarification of the subject. 
Regarding aberrant methylation, MINT loci and CDKN2A(p16) displayed a lower 
proportion (roughly half) of methylated cases for each individual marker than the 20-30% 
reported by several authors, consequently affecting CIMP+ frequency.126,171–178 
Nevertheless, some studies also reported lower MINT1 and CDKN2A(p16) methylation 
frequencies.173–175,178 One plausible explanation for these results would be a high 
proportion of rectal cancers, known to be less frequently observed in CIMP+ than colon 
tumours.119 However, in this analysis no association was found between tumour location 
and CIMP status. Importantly, CIMP+ tumours displaying MLH1 methylation and MSI 
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rarely progress to an advanced stage.178 Indeed, this finding is consistent with the high 
proportion of stage IV cases included, the frequency of MLH1 methylation was only 
0.95%, in opposition to ~15% usually reported in sporadic colorectal cancers. 
Nevertheless, many studies analysing CIMP classic panel also reported methylation 
frequencies for MLH1 substantially lower than the other four markers.126,171–173,177–179 
Moreover, differences in methodologies may explain some discrepancies. Specifically, 
the selected pair of primers and corresponding region of the CpG island in MLH1 
promoter may have underrepresented promoter methylation in this gene, as they were 
newly designed. In fact, the location of core regions and the density of methylation 
required for gene silencing can vary per gene. Thus, to overcome this limitation, a 
different pair of primers comprising a more representative region/amplicon may be used 
instead.  
Similarly, the low frequency of CIMP cases might be due to the quantitative 
technique (SYBR® Green-based real-time qMSP) herein performed, since it excludes 
most false-positive cases, leading to lower levels of methylation comparatively to non-
quantitative methodology, such as MSP. Moreover, most studies using qMSP prefer 
MethyLight as the specific quantitative technique.118,180,181 Since no CIMP studies using 
SYBR® Green-based real-time qMSP were found, direct comparisons can not be 
performed. 
Importantly, one meta-analysis including 33 studies in which CIMP was evaluated 
in CRC described a median prevalence of CIMP-positive or CIMP-high status amongst 
included studies of 18.2%, ranging from 4.6% to 46.5%.118 Therefore, the frequency of 
CIMP+ cases in our study is within the range reported. However, the same is not true 
when evaluating a trichotomized categorization of CIMP classic panel – only three cases 
were found to be CIMP-H. Nevertheless, the majority of studies testing the classic panel 
prefer the dichotomous categorization, which may be related with the specific markers 
constituting the panel. Additionally, it was suggested that either a two panel method using 
two different sets of CIMP-related markers or an eight-gene panel (such as Ogino’s 
panel) are required to properly classify CRC into one of three DNA methylation 
epigenotypes.181 Nevertheless, the indicative analysis of frequency for the three cases 
was in accordance with the literature, regarding female gender, older age and non-rectal 
location.118,120 
Interestingly, differences in ethnicity may as well explain why the prevalence of 
CIMP differs between study populations, even if the same gene panel and analytic 
methods were used in each. Indeed, English et al (2008) found that southern European 
origin individuals had lower risk of CRC CIMP+ than people of Anglo-Celtic origin, 
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possibly owing to genetic factors that are less common in people of southern European 
origin.182 
In this study no significant associations were apparent between CIMP status and 
any of the other molecular and clinicopathological variables. However, according to 
published results, CIMP-L and MINT31 methylation were significantly associated with 
mutated KRAS. Specifically, KRAS mutation has been associated with CIMP-L tumours, 
whereas CIMP+ tumours are associated with BRAF mutation.46,118,120,127 Yet, since part 
of CIMP-L tumours are also CIMP+, depending on the proportion of methylated markers 
and the threshold used for CIMP panel definition, a trend or even a significant association 
between KRAS and CIMP+ tumours may also be reported.104,127 Herein, tumours with 
two or three methylated markers were classified as both CIMP-L and CIMP+, which 
probably accounts for the trend observed for CIMP+ tumours to be KRAS mutated.  
Nonetheless, it has been suggested that BRAF and KRAS oncogene mutation 
status may refine CIMP definition.118 Therefore, an important complement to this study 
would be the screening for BRAF mutational status. 
Surprisingly, CIMP-L significantly associated with a higher number of regional 
lymph nodes with metastasis (N2), relatively to N1 tumours. Similarly, MINT1 methylation 
significantly associated with lack of lymph nodes metastasis (N0). However, due to the 
low number of tumours with methylated MINT1 promoter, N1 and N2 cases were 
combined in the same category, which precluded the comparison between N1 and N2 
cases and may have negatively affected the statistical value of the test for MINT1 locus. 
These differences are most probably due to the population analysed, since lymph node 
metastasis (N) status was not previously associated with CIMP-L or the methylation of 
this MINT loci. Moreover, CIMP-L tumours, comparatively to CIMP-H, are not as 
commonly correlated with poor prognosis120, and thus, no association with higher N stage 
is expected. 
Concerning survival analysis, several clinicopathological parameters have been 
previously described as being associated with CRC prognosis, including age, gender, 
tumour grade, depth of tumour growth, lymph node metastasis, distant metastasis and 
staging.183 Indeed, in our study, all variables but gender associated with shorter DSS. 
Moreover, neoadjuvant therapy was also independently associated with shorter DSS, 
which is related with poorer outcome of unresectable metastatic tumours. Still a great 
debate exists about the eventual outcome improvement of neoadjuvant therapy in these 
patients.184,185 Regarding DFS, only male gender was independently associated with 
poorer prognosis. These discrepancies may be at least in part explained by the 
substantial reduction of cases considered for DFS analysis. 
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It should be recalled that our cohort of patients includes a high proportion of 
tumours with advanced stages of CRC (metastatic mostly), thus impacting both in DSS 
and DFS, which is in line with a poorer prognosis depicted for stage IV tumours, in 
DSS.7,186 
Although CIMP is generally accepted as a predictor of worse prognosis, in the 
present study CIMP status showed no prognostic value both for DSS and DFS. However, 
these results follow the same trend as in a recent meta-analysis in which 13 out of 19 
studies concluded that CIMP had no significant effect on OS, and 8 of 11 studies found 
no significant relationship between CIMP and DFS.118 Moreover, in another meta-
analysis all four studies reporting the effect of CIMP in DSS, without considering any 
subgroup of patients, found no significant association between CIMP+ tumours and 
survival; and three out of four studies considering exclusively the classic panel showed 
no significant association.180 Therefore, the prognostic value of CIMP may not only 
depend on the specific population studied and the associated characteristics, but also 
according to the panel selected. 
Importantly, CIMP tumours have been strongly associated with worse outcome 
when considering only MSS and MSI-L tumours.118 However, MSI profiling was not 
performed, and therefore, it is not possible to test whether MSI status would alter the 
results, which limits the potential of this study. 
Of notice, all three CIMP-H patients died from disease progression, and two of 
them were never considered cured during the follow-up time, which is in line with the 
frequently reported association between CIMP-H and worse prognosis.120 
From all individual markers, only CDKN2A(p16) aberrant methylation significantly 
associated with poor prognosis in DSS and univariable analysis. However, significance 
was lost after multivariable analysis, which is in agreement with a large cohort study 
examining the prognostic effect of this gene promoter methylation independent of 
CIMP.187 Nevertheless, the prognostic significance of CDKN2A(p16) methylation 
independent of CIMP status remains uncertain. Specifically, a recent meta-analysis 
suggests that CDKN2A(p16) methylation might be a predictive factor for unfavourable 
prognosis of CRC patients.188 In line with this, after analysing only those cases not 
submitted to neoadjuvant therapy, an independent association between CDKN2A(p16) 
methylation and worse prognosis was found. Even though CDKN2A(p16) methylation is 
often included in the CIMP panel and is closely related to CIMP status, the reported age-
related CDKN2A(p16) methylation likely represents a confounding factor in the 
assessment of tumour-specific methylation and subsequent correlation with 
outcome.117,187 Nevertheless, as mentioned above, no correlation between 
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CDKN2A(p16) promoter methylation and age at diagnosis was found in the present 
study. 
Currently, although KRAS mutations are acknowledged as a predictive marker in 
anti-EGFR therapy, its value as a prognostic marker is highly questionable.189 In this 
dissertation, KRAS mutations did not associate with survival. However, KRAS mutations 
predicted worse prognosis in MINT31 methylated cases, whereas in CIMP-L tumours 
associated with better outcome. Nonetheless, MINT31 methylation and CIMP-L were 
both associated with improved outcome in KRAS mutated tumours. In fact, CIMP-L was 
significantly associated with contradictory outcomes in KRAS wild-type and mutated 
tumours. These intricate results may be related with the association between MINT31 or 
CIMP-L with mutation of KRAS found in our cohort of patients. However, none of these 
or other significant associations observed after stratification was described in previous 
studies. Therefore, to further clarify or validate these new findings and its possible 
implications in CRC prognostication, a new and independent series should be analysed. 
Additionally, numerous gene panel definitions, and different marker thresholds 
and laboratory methods have been used to study CIMP in CRC, which has been shown 
to result in varied CIMP frequencies and different conclusions regarding the prognostic 
value of CIMP. This lack of consensus is surely related to the still unknown biological 
cause of CIMP tumours. In addition, a difference in the choice of primers and/or the 
precise location of the region analysed to determine methylation of the marker may as 
well explain discrepancies observed between studies. Therefore, in order to further 
determine the relation between CIMP status and survival or treatment response, the 
eventual effect of MSI, BRAF, and KRAS status should be taken into consideration. 
The fact that qMSP (MethyLight) has been most frequently used alongside with 
Weisenberger’s (new) panel may point out a brittleness of the present analysis. However, 
using qMSP alongside with the classic panel instead, in fact, adds more information to 
the discussion of which is the best approach to profile CIMP in CRC. To complement this 
analysis, MSI and BRAF status should be evaluated. Analysing the same population 
following an identical approach but with a different panel or method would be of great 
importance, allowing for a more direct comparison of the potential of each panel or the 
feasibility of each laboratory technique. 
In conclusion, the analysis of CIMP status in this set of 211 CRC patients 
revealed that CIMP+ phenotype is rare in sporadic CRC and does not have an 
independent prognostic value in this malignancy. 
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APPENDIX I 
Association between represented variables and each of the five genes/loci constituting the classic CIMP panel. 
Classification of tumours according to the methylation status of each gene or locus (MINT1, MINT2, MINT31 and 
CDKN2A(p16)), and its distribution and association with all represented variables. P-values were calculated using the 
Chi-squared test or the Fisher’s exact test. Significant P-values (P<0.05) are represented in bold. Non-significant results 
for tumour invasion depth (T), distant metastasis (M), neoadjuvant and adjuvant therapies variables excluded from the 
represented table in the section “Results” are coloured in red. 
Variables MINT1 MINT2 MINT31 CDKN2A(p16) 
 M UM M UM M UM M UM 
 No. % No. % No. % No. % No. % No. % No. % No. % 
 14 6.6 197 93.4 31 14.7 180 89.6 32 15.2 179 84.8 24 11.4 187 88.6 
Gender 
Female 
Male 
 
8 
6 
 
57.1 
42.9 
 
64 
133 
 
32.5 
67.5 
 
11 
20 
 
35.5 
64.5 
 
61 
119 
 
33.9 
66.1 
 
14 
18 
 
43.8 
56.3 
 
58 
121 
 
32.4 
67.6 
 
7 
17 
 
29.2 
70.8 
 
65 
122 
 
34.8 
65.2 
 P=0.080 P=0.841 P=0.229 P=0.654 
Age 
≤61 
>61 
 
6 
8 
 
57.1 
42.9 
 
108 
89 
 
54.8 
45.2 
 
12 
19 
 
38.7 
61.3 
 
102 
78 
 
56.7 
43.3 
 
16 
16 
 
50.0 
50.0 
 
98 
81 
 
54.7 
45.3 
 
11 
13 
 
45.8 
54.2 
 
103 
84 
 
55.1 
44.9 
 P=0.418 P=0.079 P=0.701 P=0.515 
Location 
Rectum 
Distal  
Proximal  
 
6 
5 
3 
 
42.9 
35.7 
21.4 
 
98 
67 
32 
 
49.7 
34.0 
16.3 
 
18 
8 
5 
 
58.1 
25.8 
16.1 
 
86 
64 
30 
 
47.8 
35.6 
16.7 
 
14 
9 
9 
 
43.8 
28.1 
28.1 
 
90 
63 
26 
 
50.3 
35.2 
14.5 
 
14 
6 
4 
 
58.3 
25.0 
16.7 
 
90 
66 
31 
 
48.1 
35.3 
16.6 
 P=0.840* P=0.520 P=0.160 P=0.574 
KRAS  
WT 
Mutated 
ND 
 
5 
8 
1 
 
38.5 
61.5 
- 
 
109 
75 
13 
 
59.2 
40.8 
- 
 
12 
17 
2 
 
41.4 
58.6 
- 
 
102 
66 
12 
 
60.7 
39.3 
- 
 
10 
20 
2 
 
33.3 
66.7 
- 
 
104 
63 
12 
 
62.3 
37.7 
- 
 
9 
12 
3 
 
42.9 
57.1 
- 
 
105 
71 
11 
 
59.7 
40.3 
- 
 P=0.158 P=0.067 P=0.004 P=0.164 
AJCC stage 
I&II 
III&IV 
ND 
 
5 
8 
1 
 
38.5 
61.5 
- 
 
45 
151 
1 
 
23.0 
77.0 
- 
 
9 
22 
- 
 
29.0 
71.0 
- 
 
41 
137 
2 
 
22.6 
77.4 
- 
 
10 
22 
- 
 
31.3 
68.7 
- 
 
40 
137 
2 
 
22.6 
77.4 
- 
 
5 
19 
- 
 
24.9 
75.1 
- 
 
45 
140 
2 
 
24.3 
75.7 
- 
 P=0.310 P=0.496 P=0.367 P=0.804 
T 
T1&T2 
T3&T4 
ND 
 
2 
11 
1 
 
15.4 
84.6 
- 
 
20 
176 
1 
 
10.2 
89.8 
- 
 
2 
29 
- 
 
6.50 
93.5 
- 
 
20 
158 
2 
 
11.2 
88.8 
- 
 
4 
28 
- 
 
12.5 
87.5 
- 
 
18 
159 
2 
 
10.2 
89.8 
- 
 
2 
22 
- 
 
8.30 
91.7 
- 
 
20 
165 
2 
 
10.8 
89.2 
- 
 P=0.632 P=0.542 P=0.754 P=1.000 
N 
N0 
N1/(N1&2) 
N2 
ND 
 
9 
4 
- 
1 
 
69.2 
30.8 
- 
- 
 
66 
126 
- 
5 
 
34.4 
65.6 
- 
- 
 
11 
5 
14 
1 
 
36.6 
16.7 
46.7 
- 
 
64 
59 
52 
5 
 
36.6 
33.7 
29.7 
- 
 
14 
6 
12 
- 
 
43.3 
18.8 
37.5 
- 
 
61 
58 
54 
6 
 
35.3 
33.5 
31.2 
- 
 
8 
5 
11 
- 
 
25.0 
29.2 
45.8 
- 
 
67 
59 
55 
6 
 
37.0 
32.6 
30.4 
- 
 P=0.017 P=0.097 P=0.253 P=0.275 
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M 
M0 
M1 
ND 
 
5 
8 
1 
 
38.5 
61.5 
- 
 
97 
99 
1 
 
49.5 
50.5 
- 
 
17 
14 
- 
 
54.8 
45.2 
- 
 
85 
93 
2 
 
47.7 
52.2 
- 
 
15 
17 
- 
 
46.9 
53.1 
- 
 
87 
90 
2 
 
49.2 
50.8 
- 
 
12 
12 
- 
 
50.0 
50.0 
- 
 
90 
95 
2 
 
48.6 
51.4 
- 
 P=0.570 P=0.560 P=0.850 P=1.000 
Neoadjuvant 
Yes 
No 
ND 
 
5 
9 
0 
 
35.7 
64.3 
- 
 
64 
132 
1 
 
67.3 
32.7 
- 
 
13 
18 
- 
 
41.9 
58.1 
- 
 
56 
123 
1 
 
31.3 
68.7 
- 
 
11 
21 
- 
 
34.4 
65.6 
- 
 
58 
120 
1 
 
32.6 
67.4 
- 
 
6 
18 
- 
 
25.0 
75.0 
- 
 
63 
123 
1 
 
33.9 
66.1 
- 
 P=0.777 P=0.300 P=0.840 P=0.491 
Adjuvant 
No 
Yes 
 
2 
12 
 
14.3 
85.7 
 
40 
157 
 
20.3 
79.7 
 
7 
25 
 
26.6 
77.4 
 
35 
145 
 
19.4 
80.6 
 
7 
25 
 
21.9 
78.1 
 
35 
144 
 
19.6 
80.4 
 
3 
21 
 
12.5 
87.5 
 
39 
148 
 
20.9 
70.1 
 P=0.741 P=0.635 P=0.811 P=0.425 
 
APPENDIX II 
Distribution of represented variables for CRC patients not submitted to neoadjuvant therapy and association with 
CIMP status. Number of cases (and respective percentage) distributed per each category from CRC cases (N=141), 
excluding tumour grade. Dichotomous (positive/negative) and trichotomous (CIMP-0, CIMP-Low and excluding CIMP-
High) CIMP categorization, and its distribution and association with all represented variables. P-values were calculated 
using the Chi-squared test or the Fisher’s exact test. Significant P-values (P<0.05) are represented in bold. 
Variables Cases (%) CIMP- CIMP+ CIMP-0 CIMP-L 
  No. % No. % No. % No. % 
  130 92.3 11 7.7 92 64.5 46 34.1 
Gender 
Female 
Male 
 
49 (34.8) 
92 (65.2) 
 
44 
86 
 
33.8 
66.2 
 
5 
6 
 
54.4 
45.5 
 
30 
62 
 
32.6 
67.4 
 
17 
29 
 
37.0 
63.0 
  P=0.514 P=0.704 
Age at diagnosis 
≤61 
>61 
 
76 (53.9) 
65 (46.1) 
 
73 
57 
 
56.2 
43.8 
 
3 
8 
 
27.3 
72.7 
 
49 
43 
 
53.3 
46.7 
 
27 
19 
 
58.7 
41.3 
  P=0.118 P=0.589 
Tumour location 
Rectum 
Distal Colon (Colon) 
Proximal Colon 
 
50 (35.5) 
63 (44.7) [91 (64.5)] 
28 (19.8) 
 
44 
86 
- 
 
33.8 
66.2 
- 
 
6 
5 
- 
 
54.5 
45.5 
- 
 
32 
45 
15 
 
34.8 
48.9 
16.3 
 
18 
16 
12 
 
39.1 
34.8 
26.1 
  P=0.197 P=0.218 
KRAS status 
Wild-type 
Mutated 
ND 
 
73 (51.8) 
59 (41.8) 
9 (6.4) 
 
67 
54 
9 
 
55.4 
44.6 
- 
 
6 
5 
- 
 
54.5 
45.5 
- 
 
55 
32 
5 
 
63.2 
36.8 
- 
 
16 
26 
4 
 
38.1 
61.9 
- 
  P=1.000 P=0.009 
AJCC stage 
I&II 
III&IV 
ND 
 
33 (23.4) 
106 (75.2) 
2 (1.4) 
 
31 
97 
2 
 
24.2 
75.8 
- 
 
2 
9 
- 
 
18.2 
81.8 
- 
 
22 
69 
1 
 
24.2 
75.8 
- 
 
9 
36 
1 
 
20.0 
80.0 
- 
  P=1.000 P=0.668 
Tumour invasion depth (T) 
T1&T2 
T3&T4 
ND 
 
13 (9.2) 
126 (89.4) 
2 (1.4) 
 
12 
116 
2 
 
9.40 
90.6 
- 
 
1 
10 
- 
 
9.10 
90.9 
- 
 
9 
82 
1 
 
9.90 
90.1 
- 
 
4 
41 
1 
 
8.90 
91.1 
- 
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  P=1.000 P=1.000 
Lymph node metastasis (N) 
N0 
N1 (N1&N2) 
N2 
ND 
 
51 (36.2) 
39 (27.7) [87 (61.7)] 
48 (34.0) 
3 (2.1) 
 
47 
80 
- 
3 
 
37.0 
63.0 
- 
- 
 
4 
7 
- 
- 
 
36.4 
63.6 
- 
- 
 
35 
32 
23 
2 
 
38.9 
35.6 
25.5 
- 
 
13 
7 
25 
1 
 
28.9 
15.6 
55.5 
- 
  P=1.000 P=0.002 
Distant Metastasis (M) 
M0 
M1 
ND 
 
68 (48.2) 
71 (50.4) 
2 (1.4) 
 
63 
65 
2 
 
49.2 
50.8 
- 
 
5 
6 
- 
 
45.5 
54.5 
- 
 
42 
49 
1 
 
46.2 
53.8 
- 
 
24 
21 
1 
 
53.3 
46.7 
- 
  P=1.000 P=0.469 
Adjuvant therapy 
Yes 
No 
 
113 (80.1) 
28 (19.9) 
 
103 
27 
 
79.2 
20.8 
 
10 
1 
 
90.9 
9.10 
 
72 
20 
 
78.3 
21.7 
 
39 
7 
 
84.8 
15.2 
  P=0.693 P=0.495 
 
APPENDIX III 
Association between represented variables and each of the five genes/loci constituting the classic CIMP panel 
for CRC patients not submitted to neoadjuvant therapy. Classification of tumours (N=141) according to the 
methylation status of each gene or locus (MINT1, MINT2, MINT31 and CDKN2A(p16)), and its distribution and association 
with all represented variables. P-values were calculated using the Chi-squared test or the Fisher’s exact test.  
Variables MINT1 MINT2 MINT31 CDKN2A(p16) 
 M UM M UM M UM M UM 
 No. % No. % No. % No. % No. % No. % No. % No. % 
 9 6.3 132 93.7 18 12.7 123 87.3 21 14.8 120 92.2 18 12.7 123 87.3 
Gender 
Female 
Male 
 
5 
4 
 
55.6 
44.4 
 
44 
88 
 
33.3 
66.7 
 
6 
12 
 
33.3 
66.7 
 
43 
80 
 
35.0 
65.0 
 
10 
11 
 
47.6 
52.4 
 
39 
81 
 
32.5 
67.5 
 
7 
11 
 
38.9 
66.1 
 
42 
81 
 
34.1 
65.9 
 P=0.276 P=1.000 P=0.216 P=0.795 
Age 
≤61 
>61 
 
3 
6 
 
33.3 
66.7 
 
73 
59 
 
55.3 
44.7 
 
7 
11 
 
38.9 
61.1 
 
69 
54 
 
56.1 
43.9 
 
12 
9 
 
57.1 
42.9 
 
64 
56 
 
53.3 
46.7 
 
8 
10 
 
44.4 
55.6 
 
68 
55 
 
55.3 
44.7 
 P=0.302 P=0.209 P=0.815 P=0.453 
Location 
Rectum 
Colon  
 
2 
7 
 
22.2 
77.8 
 
48 
84 
 
36.4 
63.6 
 
8 
10 
 
44.4 
55.6 
 
42 
81 
 
34.1 
65.9 
 
6 
15 
 
28.6 
71.4 
 
44 
76 
 
36.7 
63.3 
 
9 
9 
 
50.0 
50.0 
 
41 
82 
 
33.3 
66.7 
 P=0.492 P=0.435 P=0.623 P=0.192 
KRAS  
WT 
Mutated 
ND 
 
5 
4 
- 
 
55.6 
44.4 
- 
 
69 
55 
9 
 
55.3 
44.7 
- 
 
9 
8 
1 
 
52.9 
47.1 
- 
 
64 
51 
8 
 
55.7 
44.3 
- 
 
7 
13 
1 
 
35.0 
65.0 
- 
 
66 
46 
8 
 
58.9 
41.1 
- 
 
6 
10 
2 
 
37.5 
62.5 
- 
 
67 
49 
7 
 
57.8 
42.2 
- 
 P=1.000 P=1.000 P=0.054 P=0.180 
AJCC stage 
I&II 
III&IV 
ND 
 
2 
6 
1 
 
25.0 
75.0 
- 
 
31 
100 
1 
 
23.7 
76.3 
- 
 
4 
14 
- 
 
22.2 
77.8 
- 
 
29 
92 
2 
 
24.0 
76.0 
- 
 
7 
14 
- 
 
33.3 
66.7 
- 
 
26 
92 
2 
 
22.0 
78.0 
- 
 
4 
14 
- 
 
22.2 
77.8 
- 
 
29 
92 
2 
 
24.0 
76.0 
- 
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 P=1.000 P=1.000 P=0.274 P=1.000 
T 
T1&T2 
T3&T4 
ND 
 
1 
7 
1 
 
12.5 
87.5 
- 
 
12 
119 
1 
 
9.20 
90.8 
- 
 
1 
17 
- 
 
5.60 
94.4 
- 
 
12 
109 
2 
 
9.90 
89.3 
- 
 
2 
19 
- 
 
9.50 
90.5 
- 
 
11 
107 
2 
 
9.3 
90.7 
- 
 
1 
17 
- 
 
5.60 
94.4 
- 
 
12 
109 
2 
 
9.90 
90.1 
- 
 P=0.554 P=1.000 P=1.000 P=1.000 
N 
N0 
N1&2 
ND 
 
5 
3 
1 
 
62.5 
37.5 
- 
 
46 
84 
2 
 
35.4 
64.6 
- 
 
6 
12 
- 
 
33.3 
66.7 
- 
 
45 
75 
3 
 
37.5 
62.5 
- 
 
9 
12 
- 
 
42.9 
57.1 
- 
 
42 
75 
3 
 
35.9 
64.1 
- 
 
6 
12 
- 
 
33.3 
66.7 
- 
 
45 
75 
3 
 
37.5 
32.5 
- 
 P=0.145 P=0.799 P=0.625 P=0.799 
M 
M0 
M1 
ND 
 
2 
6 
1 
 
25.0 
75.0 
- 
 
66 
65 
1 
 
50.4 
49.6 
- 
 
11 
7 
- 
 
61.1 
38.9 
- 
 
57 
64 
2 
 
47.1 
52.9 
- 
 
12 
9 
- 
 
57.1 
42.9 
- 
 
56 
63 
2 
 
47.5 
52.5 
- 
 
10 
8 
- 
 
55.6 
44.4 
- 
 
58 
63 
2 
 
47.9 
52.1 
- 
 P=0.275 P=0.318 P=0.481 P=0.618 
Adjuvant 
No 
Yes 
 
1 
8 
 
11.1 
88.9 
 
27 
105 
 
20.5 
79.5 
 
3 
15 
 
16.7 
83.3 
 
25 
98 
 
20.3 
79.7 
 
5 
16 
 
23.8 
76.2 
 
23 
97 
 
19.2 
81.8 
 
2 
16 
 
11.1 
88.9 
 
26 
97 
 
21.1 
78.9 
 P=0.688 P=1.000 P=0.568 P=0.527 
 
APPENDIX IV 
Univariable and multivariable prognostic analyses: disease-specific survival analysis of CRC patients not 
submitted to neoadjuvant therapy according to represented variables and CIMP panel/markers methylation. 
Multivariable analysis was performed considering only those variables presenting a P-value<0.05 in the univariable 
analysis (excluding T, N and M stages). Significant P-values (P<0.05) are represented in bold. 
Variables Univariable analysis Multivariable analysis 
 HR (95 % CI) P HR (95 % CI) P 
Gender 
Female (49) 
Male (92) 
 
1 (referent) 
0.877 (0.598-1.286) 
 
- 
0.502 
  
Age 
≤61 (76) 
>61 (65) 
 
1 (referent) 
1.544 (1.072-2.222) 
 
- 
0.020 
 
1 (referent) 
1.523 (1.046-2.217) 
 
- 
0.028 
Location 
Rectum (50) 
Distal (63) 
Proximal (28) 
 
0.789 (0.455-1.199) 
0.739 (0.419-1.131) 
1 (referent) 
0.318 
0.141 
0.221 
- 
  
KRAS 
WT (73) 
Mutated (59) 
 
1 (referent) 
0.872 (0.596-1.274) 
 
- 
0.478 
  
AJCC stage 
I & II (33) 
III (35) 
IV (71) 
 
0.525 (0.332-0.830) 
0.571 (0.365-0.891) 
1 (referent) 
0.006 
0.006 
0.014 
- 
 
0.481 (0.303-0.763) 
0.513 (0.326-0.807) 
1 (referent) 
0.001 
0.002 
0.004 
- 
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T 
T1&T2 (13) 
T3 (115) 
T4 (11) 
 
0.176 (0.074-0.416) 
0.185 (0.094-0.360) 
1 (referent) 
<0.001 
<0.001 
<0.001 
- 
  
N 
N0 (51) 
N1 (39) 
N2 (48) 
 
0.583 (0.382-0.892) 
0.580 (0.362-0.929) 
1 (referent) 
0.020 
0.013 
0.023 
- 
  
M 
M0 (68) 
M1 (71) 
 
1 (referent) 
1.826 (1.264-2.637) 
 
- 
0.001 
 	
Grade 
G1&2 (119) 
G3 (5) 
 
1 (referent) 
2.424 (0.975-6.026) 
 
- 
0.057 
 	
Adjuvant 
Yes (113) 
No (28) 
 
1.510 (0.948-2.406) 
1 (referent) 
 
0.083 
- 
  
CIMP 
Positive (11) 
Negative(130) 
 
1.471 (0.790-2.741) 
1 (referent) 
 
0.224 
- 
  
CIMP 
CIMP-0 (136) 
CIMP-L (71) 
 
1 (referent) 
0.826 (0.559-1.222) 
 
- 
0.338 
  
MINT1 
M (9) 
UM (132) 
 
1.141 (0.572-2.275) 
1 (referent) 
 
0.707 
- 
  
MINT2 
M (18) 
UM (123) 
 
0.851 (0.493-1.468) 
1 (referent) 
 
0.561 
- 
  
MINT31 
M (21) 
UM (120) 
 
0.674 (0.402-1.130) 
1 (referent) 
 
0.134 
- 
  
P16 
M (23) 
UM (187) 
 
1.791 (1.080-2.971) 
1 (referent) 
 
0.024 
- 
 
1.838 (1.090-3.097) 
1 (referent) 
 
0.022 
- 
	
APPENDIX V 
Univariable and multivariable prognostic analyses. Disease-specific survival (DSS) analysis of CIMP+, CIMP-0 or 
CIMP-L CRC patients according to other clinicopathological and molecular variables. Multivariable analysis was 
performed considering only those variables presenting a P-value<0.05 in the univariable analysis (excluding T, N and M 
stages). Significant P-values (P<0.05) are represented in bold. 
Variables Univariable analysis Multivariable analysis 
 
CIMP+ CIMP-0 CIMP-L 
HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P 
Gender 
Female 
Male 
 
1 (referent) 
2.189 (0.803-5.967) 
 
- 
0.126 
    
Age 
≤61 
>61 
 
1 (referent) 
1.262 (0.440-3.623) 
 
- 
0.665 
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Location 
Rectum 
Distal (Colon) 
Proximal 
 
0.630 (0.226-1.755) 
[1 (referent)] 
- 
 
0.376 
- 
- 
 
0.336 (0.186-0.608) 
0.364 (0.203-0.653) 
1 (referent) 
0.001 
<0.001 
0.001 
- 
  
KRAS 
WT 
Mutated 
 
1 (referent) 
0.525 (0.184-1.499) 
 
- 
0.229 
  
 
1 (referent) 
0.414 (0.234-0.733) 
 
- 
0.002 
AJCC stage 
I & II 
III (III&IV) 
IV 
 
0.357 (0.112-1.132) 
[1 (referent)] 
 
0.080 
- 
 
0.485 (0.291-0.807) 
0.572 (0.359-0.910) 
1 (referent) 
0.008 
0.005 
0.018 
- 
  
T 
T1&T2 
T3&T4 
 
- 
- 
 
- 
- 
    
N 
N0 
N1&N2 
 
0.584 (0.458-0.922) 
1 (referent) 
 
0.282 
- 
    
M 
M0 
M1 
 
1 (referent) 
10.86 (2.279-51.72) 
 
- 
0.003 
 
 
 	
Neoadjuvant 
Yes 
No 
 
0.701 (0.257-1.912) 
1 (referent) 
 
0.488 
- 
  
 
2.068 (1.134-3.772) 
1 (referent) 
 
0.018 
- 
Adjuvant 
Yes 
No 
 
- 
- 
 
- 
- 
    
 
APPENDIX VI 
Univariable prognostic analyses. Disease-specific survival (DSS) analysis for CRC patients with methylation of 
MINT2, MINT31 or CDKN2A(p16) promoters according to other clinicopathological and molecular variables. Only 
those variables presenting a P-value<0.05 in the univariable analysis are represented. Significant P-values (P<0.05) are 
represented in bold. 
Variables MINT2 MINT31 CDKN2A(p16) 
 HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P 
KRAS 
WT 
Mutated 
  
 
0.358 (0.156-0.822) 
1 (referent) 
 
0.015 
- 
  
AJCC stage 
I & II 
III 
IV 
 
0.896 (0.378-2.122) 
0.300 (0.106-0.853) 
1 (referent) 
0.068 
0.802 
0.024 
- 
  
 
0.309 (0.100-0.952) 
0.326 (0.102-1.037) 
1 (referent) 
0.061 
0.041 
0.058 
- 
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APPENDIX VII 
Univariable prognostic analyses. Disease-specific survival (DSS) analysis for male patients, patients that were 
61 or younger or patients with tumour located in the proximal colon, according to CIMP panel/markers 
methylation. Only those variables presenting a P-value<0.05 in the univariable analysis are represented. 
Variables Male ≤61 Proximal colon 
 HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P 
CIMP 
CIMP-0 
CIMP-L 
 
 
  
 
1 (referent) 
0.369 (0.168-0.810) 
 
- 
0.013 
P16 
M 
UM 
 
1.734 (1.020-2.946) 
1 (referent) 
 
0.042 
- 
 
2.168 (1.105-4.253) 
1 (referent) 
 
0.024 
- 
  
 
APPENDIX VIII 
Univariable prognostic analyses. Disease-specific survival (DSS) analysis for patients with KRAS WT patients, 
patients with mutated KRAS or patients not submitted to adjuvant therapy, according to CIMP panel/markers 
methylation. Only those variables presenting a P-value<0.05 in the univariable analysis are represented. 
Variables KRAS WT KRAS Mutation No Adjuvant 
 HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P 
CIMP 
CIMP-0 
CIMP-L 
 
1 (referent) 
1.871 (1.159-3.021) 
 
- 
0.010 
 
1 (referent) 
0.554 (0.343-0.893) 
 
- 
0.015 
  
MINT31 
M 
UM 
 
  
0.535 (0.305-0.938) 
1 (referent) 
 
0.029 
- 
 
0.377 (0.144-0.984) 
1 (referent) 
 
0.046 
- 
 
